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Abstract 
 
Ovarian carcinoma afflicts over 22,000 women each year with a 5 year survival rate of 
only 18% for stage IV patients [23].  Current treatment options are limited due to high rates of 
drug resistance and recurrence.  Further, the identity of “precursor lesions” which give rise to 
various subclasses of epithelial ovarian cancer has been evasive.  This is due to discovery of the 
cancer at already an advanced stage.   Interestingly, endometriosis a benign but invasive 
gynecological disease has been described as a “precursor lesion” in the development of specific 
subtypes of ovarian cancer.   Endometriotic cyst development involves the accumulation of “old 
blood” components including iron-rich heme. Published evidence implicates excess iron that is 
involved in the transformation of normal surface epithelial cells inducing morphological 
characteristics of clear cell ovarian cancer cells [13, 34].  Due to excess iron in endometriotic 
cysts, this essential element may play a transformative role in the development of clear cell 
ovarian cancer and possibly other subtypes [13, 35-38].  Further, studies show increased risk of 
developing ovarian cancer, particularly clear cell and endometrioid ovarian subtypes, in patients 
diagnosed with endometriosis [36, 37, 39, 40] . 
 This thesis aims to initiate an investigation regarding the contribution of iron and 
endometriotic lesions in the development and progression of specific subtypes of epithelial 
ovarian cancers.  Since there is a lack of well-validated and characterized endometriotic cell lines 
that could be used for endometriosis studies, we sought to develop an immortalized cell line for 
future endometriotic in vitro and in vivo studies.  Thus, in Chapter 3 we present our efforts in 
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developing a novel life-span extended epithelial endometriotic cell line.  The cells were derived 
from the endometriotic tissue of a patient with endometriosis.  We describe our attempts at 
immortalization and the characterization of this endometriotic cell line in relation to previously 
reported/available endometrial/endometriotic cell lines. 
 In Chapter 4 we investigated the role of iron in modulating functional aspects of various 
gynecological cell lines.  Although our expectation was that iron could transform normal ovarian 
surface epithelial cells (OSE) to a carcinoma-like phenotype, we instead discovered that ovarian 
cell lines containing Ras mutations (or with H-Ras overexpression) responded to iron (presented 
as ferric ammonium citrate (FAC)) with a reduced growth response.  Further treatment with iron 
induced an apoptotic/necrotic death response in the Ras mutated HEY ovarian carcinoma cell 
line.  Interestingly, we identified that iron induced autophagic activation in all ovarian cell lines 
investigate, although autophagy contributed only modestly to the cell death event.  Furthermore, 
we noted that iron activated the MAPK pathway and its inhibition (via U0126, a MAPK 
inhibitor) allowed survival of cells.     
 In Chapter 5, we briefly explore the role of iron in ovarian cell types growing under 
anchorage-independent conditions.  We found that the cell lines displayed increased cleaved 
PARP and apoptosis when placed under these conditions.  Treatment with iron led to a reduction 
in cleaved PARP suggesting that iron promotes cell survival in anchorage-independent 
conditions.  Further, inhibition of autophagy via chloroquine led to increased cleaved PARP 
suggesting that autophagy may mediate a protective role against anchorage-independent 
apoptotic response    
 In Chapter 6, we attempted to elucidate the downstream mechanism following 
Ras/MAPK activation in response to iron. This study identified several signaling pathways 
xi 
 
including that involved in translational control, iron metabolism, as well as mitochondrial 
function.  The inhibition of the iron regulatory and translation control pathway did not 
significantly lead to rescue of iron-induced cell death of Ras mutated/overexpressed cells.  
However, we noted mitochondrial stress and damage including altered expression of 
mitochondrial markers (TOM20/TOM70, outer membrane transporters) which occurred 
concurrently with iron-induced cell death.  The inhibition of iron import into mitochondria using 
a calcium uniporter channel inhibitor (Ru360) led to a marked reversal of the cell death response.  
Collectively, these studies suggest that increased mitochondrial permeabilization may be 
responsible for the observed iron-induced cell death response.    
Overall, the studies presented in this thesis have revealed novel responses to iron in the 
gynecological cell types investigated.   We initially sought to understand the role of iron in 
precursor lesions which included the development of a novel life-span extended epithelial 
endometriotic cell type.  Remarkably, our findings revealed a Ras driven sensitivity to excess 
iron.  Treatment with iron caused decreased cell growth and increased cell death in cell types 
containing Ras mutation/overexpression.  Further, we found that the mechanism leading to the 
iron-induced cell death events was mediated via the MAPK pathway.  We then determined that 
the cell death response was associated with mitochondrial permeabilization.  Loss of 
mitochondrial integrity occurred in Ras sensitive cell lines and inhibition of iron import into the 
mitochondria (via the calcium uniporter channel inhibitor, Ru360) led to reversal of this 
response.  We show herein the cellular response of excess iron and its potential implication in 
ovarian cancer research.     
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Chapter 1 
 
Introduction 
 
Ovarian Cancer 
Ovarian cancer is the 5
th
 most common cancer affecting over 22,000 women each year 
and leading to another 14,000 deaths [23].   Tactics to treat the disease include surgical 
debulking of the tumor including the removal of the ovaries in combination with chemotherapy 
(paclitaxel/cisplatin) [23, 41, 42].  Unfortunately, the disease often remains asymptomatic until 
reaching an aggressive phenotype [23].   Since the cancer is detected in late stages, resistance to 
chemotherapy is frequent and the mortality rate is high [43].   This highlights the critical need to 
not only study ovarian cancer but to develop novel therapeutics to assist in combating resistance, 
metastasis, and overall tumorigenesis.   
Ovarian cancer is a heterogeneous disease since it is comprised of a large array of cancer 
subtypes [23, 44].   On a broad scope, three types of ovarian tumors exist: (1) germ cell, (2) 
stromal, and (3) epithelial [23].   Germ cell tumors develop in the ovary from the ova [23, 45].   
These tumors are typically benign and appear early stage in reproductive life (early 20s) [23, 45].   
Often these tumors can be removed without re-occurrence or loss of fertility [23].  Stromal-
derived ovarian cancers are also typically benign or low grade [23].   These tumors often develop 
due to hormone dysregulation leading to abnormal stromal cell growth [7].   The frequency of 
epithelial ovarian carcinoma (EOC) far exceeds that of germ cell or stromal tumors; EOC is 
2 
 
believed to account for over 90% of the malignant ovarian cancer patient population [23].  
Unfortunately, EOC also accounts for the highest mortality rate primarily due to being 
undetected until advanced stages (see Figure 1) [23].  The frequency and mortality rate 
associated with epithelial ovarian cancers is strikingly high; therefore, we focused our studies on 
this disease [23]. 
    
            
 
          
 
 
As with ovarian cancer, EOC can be broken down into various subgroups which are 
based on characteristics as well as origin of cancer type [23].  Epithelial ovarian subtypes include 
(1) serous, (2) endometrioid, and (3) clear cell.   Serous carcinoma is the most common form of 
EOC, comprising ~70% of the patient population [23, 40].   Serous carcinoma can be subdivided 
into high and low grade states [46].   Low grade serous carcinoma has frequent mutations in K-
Figure 1: Model of ovarian cancer progression.    
Ovarian cancer progression is classified by both grade and location of the 
disease.  The cancer will be graded high if it is more invasive and less 
differentiated.  This chart represents stage and grade information obtained 
from cancer.gov [23]. 
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Ras and BRAF but lacking in p53 mutations [23, 46].   Low grade serous derives from 
adenofibromas and/or early stage tumors [23, 40].  This form of serous carcinoma is considered 
slow growing relative to its high grade counterpart.  High grade serous carcinoma is 
characterized by its high mutation levels along with being multinucleated [23].  Interestingly, a 
large number of studies have demonstrated that serous carcinoma (specifically high grade) has 
many morphological similarities to those of the fallopian tube [46, 47].  These studies suggest 
that the origin of serous carcinoma arises from outside of the ovaries.   
Clear cell and endometrioid carcinoma account for about 20% of the EOC patient 
population [23].   Both subtypes are considered to derive from endometrial lining tissue [36, 38].   
One potential explanation for the movement of endometrial tissue to the ovary is retrograde 
menstruation [36, 39, 40].   This leads to the development of endometriotic lesions; this results 
from the menstrual lining traveling upward into the fallopian tube and attaching either to the 
fallopian tube itself, the ovaries, or the peritoneal cavity [38].  Endometriotic tissue then 
continues and then may eventual lead to the formation of endometriotic cysts [36-38].   The 
cellular contents of the cysts can develop mutations leading to formation of clear cell borderline 
tumors and then a more aggressive cancer [13, 17, 18, 34, 35].  A factor that may contribute to 
this process is the presence of high blood content within the endometriotic cyst [13].   
Interestingly, this blood is rich in iron and is marked by the cysts’ dark brown coloration which 
has been termed “chocolate” cysts [13, 34].  Free radical iron promotes the transition of normal 
cell morphology to clear cell carcinoma phenotype [13].   Although the percentage of clear cell 
ovarian cancer patients is lower than serous, clear cell is comparatively more chemoresistant and 
aggressive which makes this rarer form of  ovarian cancer a critical area to study [23, 48].  
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Endometriosis  
Endometriosis may be a precursor lesion leading to the development of ovarian 
carcinoma [36-39, 49]. Studies have shown that women with endometriosis have up to a 40% 
risk of this ailment developing into ovarian carcinoma [36, 37, 49].   Of this group, the majority 
of patients had clear cell or endometrioid ovarian carcinoma [36, 37, 49, 50].    Interestingly, 
endometriosis is a common gynecological disease occurring in millions of women each year with 
some reports suggesting over 10% of the female population are afflicted [51].  Similarly to 
ovarian cancer, endometriosis is typically diagnosed after the emergence of abdominal and 
pelvic pain [51].  Further, endometriosis can also lead to infertility [51].    
Classically, endometriosis is believed to derive from the endometrial lining of the uterus 
[36, 37, 51, 52].  This tissue is sheathed during the estrus cycle allowing for the development of a 
new lining.   In endometriosis, this tissue travels upward into the uterus then into the fallopian 
tube and then adheres to the ovaries.   This phenomenon was first observed by Dr. John Sampson 
in the 1920s [53].   Since then, these findings have been corroborated and are generally accepted 
as the primary cause of the disease [51].   Endometriosis can also develop elsewhere; not only in 
the ovary but outside of the pelvic area, implicating other theories in the development[51].  One 
leading hypothesis states endometriosis can arise from the ovary itself [52].   This process is 
called celomic metaplasia which involves the transformation of the ovarian surface epithelial 
cells (OSE) to endometrial-like cells [52].       
Intriguingly, the development of endometriosis parallels that of ovarian cancer and other 
cancers in general.   Endometriosis develops from endometrial cells migrating  from its site of 
origin which grow in a new locations (fallopian tube, ovaries, peritoneal cavity) (See Figure 2) 
[37]. 
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Figure 2: Model of endometriosis progression.  
Endometriosis can developed into an endometriotic cyst leading to 
accumulation of heme.  This heme can be broken down via Heme Oxygenase-
1 (HO-1) leading to release of free iron and increase of ROS.  Consistent 
exposure to ROS may induce mutations allowing for the development of 
ovarian cancer [12-18].  *Model created by Kyle Bauckman. 
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While these lesions are typically limited to gynecological tissue, many studies have 
shown endometriosis has the ability spread to the pelvic region: abdominal cavity, lung, skin, 
and colon [36, 37, 50, 52].   Endometriosis, like cancer, also has a staging system with various 
grades from stage I (minimal) to stage IV (severe) [51].  Interestingly, the only key difference 
between endometriosis and cancer is the former’s retention of cell cycle control [54]. 
The development of endometriosis is a multifactorial event.  While the exact steps 
required for endometriosis to develop are not fully understood, it is known that a combination of 
genetic and environmental events are critical (see Figure 2) [51].   Endometriosis can be 
inherited and is linked to specific genetic mutations including mutations including those in 
chromosome 7 and 10 [55].  Low levels of the hormone progesterone and decreased 
progesterone receptors may increase risk of the disease [51].   Environmental factors can also 
lead to development of this disease.  Toxins such as dioxins (found in pesticides) have been 
connected to increased risk of endometriosis [56].  Interestingly,  the risk of endometriosis is 
greatly reduced after menopause which is converse to ovarian cancer risks [23, 51].   Since 
endometriosis derives from sheathed endometrial tissue, the advent of menopause halts this 
process.   
 Endometriosis is classified into four grades which are based on location, size, and 
number of lesions [51].   Stage I is considered a minimal level of endometriosis with only one to 
two small lesions localized to one site [51].   In contrast, stage IV patients have large and 
numerous lesions located throughout the peritoneal cavity [51].  The tissue growth (size and 
area) is also quite massive making it difficult to remove.  Patients with stage IV often have 
atypical lesions present within a highly inflammatory environment [33, 36, 37, 51].   These 
patients are particularly vulnerable to the development of ovarian cancer.  Treatment strategies 
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are dependent on the grade of the disease;  this can range from hormone therapy (addition of 
progesterone or estrogen ablation) and surgery (removal of the endometriotic mass) [51].   
Another argued, means of preventing and reducing endometriosis is pregnancy [51].   This likely 
is due to the increased progesterone produced during pregnancy creating a natural defense 
against endometriosis.   
 Strikingly, a large subset of the endometriosis patient population ends up developing 
cancer.  Many studies have shown a large portion (~40%) of the clear cell carcinoma patient 
population had endometriosis prior to carcinoma development [16-18, 34, 36, 37, 39, 40, 49, 50].  
These findings, however, are quite variable due to the difficulty in diagnosing endometriosis and 
ovarian cancer.   Typically, the identification of similar histologic patterns between the 
malignancy and endometriosis results in positive confirmation of the association [36-38, 50].  
Often patients only show symptoms after the cancer has spread from the site of origin and 
beyond.  This makes it challenging to isolate and validate any tissue that might be endometriosis.   
Transformation from endometriosis to ovarian cancer can occur via environmental and 
genetic factors.  One hypothesis states that endometriosis develops into an endometriotic cyst in 
the ovary which leads to cell stress and drives cancer formation [13, 18, 31, 34].   Atypical 
endometriosis is correlated with the presence of metaplasia, hyperplasia, and cytological atypia 
[57, 58].  Interestingly, atypical endometriosis is associated with mutations and/or modifications 
such as increased HNF1β expression, deletion of ARID1a, and increased estrogen receptor 
expression [14, 59].   These events may lead to atypical lesions formation and appears to be a 
critical event in the transition to cancer.  Further, mutations of p53, K-Ras, and deletion of PTEN 
are critical for the transition from endometriosis to early forms of ovarian cancer (see Figure 2) 
[12, 14, 60, 61].    
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As mentioned, transformation of an endometriotic cyst to aggressive clear cell carcinoma 
is hypothesized to occur partly due to excessive iron exposure (see Figure 2) [13].   Excess iron 
present in “chocolate” cysts produces free radical iron which leads to a dramatic increase of ROS 
[13].  This increased ROS activity then leads to cell stress and subsequent mutations, 
transforming the benign cyst into one with more aggressive characteristics.  Since iron appears to 
be an important factor in meditating these events, we initiated an investigation into the cellular 
response of iron in normal gynecological and cancer cell types.   Elucidation of the cell signaling 
pathways triggered by iron in ovarian cells may help to understand its role in modulating cellar 
transformation.    
 
Iron Signaling Pathway 
Iron can be both beneficial and detrimental to cellular survival; it is critical for protein 
production, protein activity, and ATP production while also increasing oxidative stress [19, 25].  
Due to iron’s multiple oxidation states, the element is very important in numerous biochemical 
reactions throughout the body [19, 26].  This includes large scale events such as the transport of 
oxygen via hemoglobin to micro events such as ATP production [19].   This same oxidative 
flexibility, however allows for iron to cause oxidative damage and production of reactive oxygen 
species.   Fortunately, evolution has developed mechanisms for strict regulation of iron 
utilization, storage, and removal that would reduce the detrimental effects of iron exposure [19].   
Dysregulation of this iron control pathway could induce negative effects including cell death 
and/or tumor development [25].    
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The iron regulatory pathway is broken down into four functions: intake, storage, 
utilization, and removal [25].   The primary mechanism of obtaining iron occurs through 
consumption of products containing iron or through blood containing iron-rich heme.  Iron can 
bind to transferrin (an extracellular protein that recruits and shuttles iron) creating a complex that 
can associate with the transferrin receptor (CD71) (see Figure 3) [25].   CD71 association with 
Figure 3: Model of Iron Signaling Pathway.   
Iron can enter the cell by interaction with transferrin.  Iron can then be shuttled 
to the transferring receptor.  This interaction induces the formation of an 
endosome in which iron loses association with the transferrin receptor and is 
converted into its active Fe
+2
 form.   This is due to the acidic environment of 
the endosome. Iron can be shuttled into the cytosol via the Divalent Metal 
Transporter-1.   Once in the cytosol, iron becomes part of the labile iron pool 
which can be utilized for basic cell functions.    Excess iron is stored via 
ferritin preventing excess iron from creating ROS.   Iron may also be shuttle 
out of the cell via ferroportin [25, 26].  *Model created by Kyle Bauckman. 
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iron bound to transferrin leads to endosome formation and thus, the  cellular internalization of 
iron (See Figure 3) [25].   Iron is released in the endosome as Fe
+2 
(this occurs via the action of 
STEAP3 [25]) and can be transferred into the cytoplasm via the divalent metal transporter 
(DMT-1) (See Figure 3) [25].   This iron is then free to interact in the cell to elicit its effects via 
protein production, mRNA silencing, or utilization in the mitochondria [19, 25].   Iron can also 
be stored via the protein ferritin (see Figure 3).  This protein binds to iron, converting it to a less 
reactive state, Fe
+3
.  This iron can be stored in the cell for future use.  Ferritin is found in varying 
levels and consists of heavy and light chain isoforms in different cell types [25].  The heavy and 
light chains are important in iron storage, but the ratio varies [25].  Some cells express high 
levels of the heavy chain (i.e. the heart) while others contain higher levels of the light chain (i.e. 
liver) [25].  It has been speculated that the heavy chain may dominate in cells that utilize iron 
more for metabolic purposes whereas the light chain may dominate in cells that manage iron 
toxicity (via iron storage) [25].  If iron bound to ferritin is required for utilization, it will be 
consumed by lysosomes and free iron (Fe
+2
) is released.  If the cell contains an excess of iron 
beyond the capacity of ferritin storage, the cell can expel iron extracellularly via ferroportin (See 
Figure 3) [19, 25].   This transmembrane protein is critical for the expulsion of excess iron 
preventing accumulation of intercellular free iron.   Ferroportin is regulated by the small 
hormone peptide hepcidin (see Figure 3) [25, 27].   Hepcidin is considered the “master regulator” 
of iron in the body [27].  It is produced via the liver and acts as an endocrine hormone [27].  
Hepcidin promotes the internalization and degradation of ferroportin thus preventing iron from 
being exported out of the cell [27].  This allows for cells to retain iron under iron scarce 
conditions.  
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Mitochondria also have a complex role in iron regulation.   Iron can be imported through 
mitochondrial transport complexes including the calcium uniporter channel (see Figure 4)   [62, 
63].  Once inside the mitochondria, iron can be utilized for multiple functions including heme 
biosynthesis, storage (via mito-ferritin), and production of iron sulfur complexes (ISCs) (see 
Figure 4) [21, 64].   Heme synthesis is mediated by frataxin, a regulatory protein involved of 
iron-sulfur cluster biogenesis, leading to  
                                     
 
 
 
 
      
 
 
Figure 4: Model of iron regulation in the mitochondria.   
Iron can enter the mitochondria through the mitochondrial membrane 
uniporter channel along with other transport mechanism.  Once in the cell, iron 
is regulated by frataxin to be utilized for heme biosynthesis or iron sulfur 
cluster formation.  Iron may also be stored via mito-ferritin (mt-Ferritin).   Iron 
sulfur clusters are formed via ferredoxin and frataxin.  In this process, cysteine 
donates sulfur leading to four iron particles interacting with one sulfur particle.   
The donation of sulfur results in cysteine becoming alanine [20-22].  *Model 
created by Kyle Bauckman. 
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production and export of the product (see Figure 4) [21, 25].   Mito-ferritin functions similarly to 
its cytoplasmic counterpart where it stores excess iron safely for future utilization (see Figure 4)  
[25].  The formation of iron sulfur-complexes is another critical process in mitochondrial 
functions.  Iron-sulfur complexes are utilized for protein regulation and translation [21, 25].  
ISCs are created by binding one sulfur molecule with four iron molecules (see Figure 4).   ISCs 
are particularly important in the activity of aconitase.   This is an enzyme critical in the 
regulation of the citric acid cycle and thus important in ATP production and the overall 
metabolic state of the cell [21, 25]. 
 
 
 
 
 
 
 
Multiple proteins (including those important for regulating iron) are transcriptionally 
controlled by iron regulatory proteins (IRPs) (see Figure 5) [19].   Two types of IRPs regulate 
transcription [19].  While both play similar roles in regulation, IRP1 is regulated by ISCs 
whereas IRP2 is not; IRP1 is associated aconitase activity while IRP2 is not.  This suggests that 
IRP1/2 may regulate iron dependent proteins differently, though studies vary on which IRP 
protein is the most important [19].   Overall, IRPs ability to bind to specific proteins is dependent 
Figure 5: Model of iron regulatory mechanism.    
Iron Response Proteins (IRP1/2) interact with Iron Regulatory Elements 
(IREs) of specific mRNAs. IRPs serve a dual purpose in mRNA regulation.   
IRPs can interact with IREs in the untranslated regions of mRNA leading to 
repression of protein production (ferritin H/L) or help to stabilize the mRNA 
during transcription (transferrin receptor).  In the presence of high iron, iron 
sulfur clusters can interact with IRPs leading to dissociation from the IRE 
sites. This leads to activation of repressed proteins and destabilization of 
others [19].   *Model created by Kyle Bauckman. 
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on the level of iron in the cell.  For example, under low iron conditions, IRPs bind to the 5’ 
untranslated region (UTR) of ferritin suppressing its translation (see Figure 5).  When iron is 
present in high levels, ISCs bind to IRPs preventing its ability to bind to the UTR promoting 
translation (see Figure 5) [19].   The trend described with ferritin is different in relation to CD71 
[19].  IRPs bind to the 3’UTR region of CD71 mRNA in low iron levels, thus promoting its 
translation (see Figure 5).  In contrast, under iron rich conditions, the IRPs are released from the 
3’UTR of CD71 leading reduced translation [19].    
On a global level, iron can be shuttled throughout the body via heme (in a large complex 
called hemoglobin) [9, 10, 21].   Heme can be broken down in cells (commonly in macrophages) 
via the enzyme heme oxygenase-1 (HO-1) (see Figure 6) [9].  HO-1 is a rate limiting enzyme  
       
 
 
 
 
 
Figure 6: Model of heme regulation.   
Heme breakdown is dependent on the rate limiting enzyme heme oxygenase-1.  
This enzymatic process results in reduced iron (Fe
+2
), biliverdin, and carbon 
monoxide as byproducts [9, 10].  *Model created by Kyle Bauckman. 
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that catalyzes the breakdown of heme into free Fe
+2
, biliverdin, and carbon monoxide (see Figure 
6) [9]. Interestingly, high levels of biliverdin and the degraded byproduct, bilirubin, elicit 
antioxidant benefits [9, 65].  Some studies even show that high levels of bilirubin lead to 
increased life span and decreased risk of heart disease [66, 67].   
Iron dysregulation is mediated by multiple mutations leading to a variety of cell 
responses.   One of the most common iron associated diseases is Friedreich’s ataxia [68].   This 
is a mitochondrial related disease that specifically involves the mutation of frataxin [68].  
Patients are born with a mutation in this gene which leads to metabolic disorders and heart 
conditions.  Iron leads to the development of cancer [68].    
Increased presence of iron in normal ovarian cells has been shown to lead to a change to 
a clear cell like morphology [13, 25, 27, 34, 69, 70].  Indeed, iron is capable of producing ROS 
due to its free radical nature.  Consistent exposure to ROS may increase inflammatory signals 
and thus induce DNA damage [34].  Further, many reports have shown that cancer cells 
intentionally acquire high levels of iron [25, 71].  This is likely due to the faster metabolic rate 
compared to normal cell types.  Multiple studies have shown that breast cancer cells utilize iron 
for beneficial purposes; a mechanism may be hepcidin which promotes for increased intercellular 
iron [25, 69].    
 
Mechanisms of Cell Death 
Though iron plays a tumorigenic role in the body, we have found that iron can adversely 
affect cell growth in ovarian cell types with Ras mutated/overexpression (see Chapter 4).   
Similar phenomenon have also been reported in other cell types, but the exact mechanism of 
iron-induced death is poorly understood [71].  We thus wanted to investigate previously 
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established mechanisms of iron associated death as well as contribute new knowledge to the 
field.   
Types of programmed cell death mechanisms can be broken down in three major 
categories.  Apoptosis is the most classic form of cell death [72].   This process is activated in 
response to multiple environmental factors including DNA damage, mitochondrial dysregulation, 
and cytokine signaling [72].   Apoptotic cells can be easily identified by their distinct membrane 
blebbing and spherical appearance.  Apoptotic cell death can occur in an intrinsic and extrinsic 
manner [72].  Extrinsic apoptosis may also involve loss of cytochrome c via the mitochondria.  
Extrinsic apoptosis’ striking difference is that death cues occur from outside elements while 
intrinsic death occurs from internal cell activity.  Intrinsic apoptosis is mediated by the 
mitochondria, particularly due to loss of cytochrome c [72].  This leads to activation of caspases 
9 and 3, leading to cell death.   In contrast, extrinsic cell death is regulated by external cytokines 
such as TNF and TGF.  These inflammatory signals can induce a caspase 8 dependent cell death.  
Extrinsic apoptosis may also involve loss of cytochrome c via the mitochondria.  Apoptosis can 
also be induced by detachment from the extracellular matrix; this is termed anoikis, a type of 
apoptotic cell death [72-75].  Anoikis is particularly interesting since resistance to this death 
leads to metastasis in vivo [73, 74, 76, 77].  While a normal cell would die after becoming 
detached from its extracellular matrix, a cancer cell can continue to survive.  The loss of 
adhesion allows the cancer cell to travel through the body to a distant site, attach, and continue to 
divide allowing the secondary tumor to grow.    
  Macroautophagy (called autophagy herein) is another major regulator of cell death [72, 
78, 79].  Unlike apoptosis, autophagy has a dual purpose; inducing cell death as well as 
promoting cell survival [79].   Autophagosomes are induced to breakdown and recycle damaged 
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organelles and proteins (see Figure 7).   These proteins induce the production of autophagosomes 
via autophagy regulatory proteins.   These regulatory proteins help form the phagophore that  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Model of autophagy regulation.  
Autophagy can be induced by metabolic signals (AMPK), genomic stress, and 
modulation of BCL-2.  Induction of autophagy leads to the formation of a 
phagophore that is utilized to sequester damaged organelles and proteins.   
Autophagy proteins convert LC3 to LC3-I and finally LC3-II.  This occurs via 
lipidation of LC3 by autophagy proteins (ATG4, ATG3, ATG7).   This is then 
recruited to the autophagosome membrane.  Finally, the autophagosome fuses 
with a lysosome to create an autophagolysosome.  The fused entity then 
degrades the damaged contents and recycles them into free amino acids and 
nutrients [24].  LC3-II is degraded after fusion of the lysosome with the 
autophagosome via lysosome hydrolases [24].  *Model created by Kyle 
Bauckman. 
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engulfs damaged organelles and proteins.  Autophagosomes can be easily detected by its double 
bound membrane using transmission electron microscopy (TEM) [79].  Once a complete 
autophagosome is formed, it can fuse with a lysosome creating an autophagolysosome (see 
Figure 7) [72].   This complex degrades the organelles and proteins into free amino acids and 
nutrients that can be utilized in the cell.  In this sense, autophagy is a cell protective mechanism 
removing unwanted/damaged material from the cell [79].  However, if the cell contains a large 
amount of organelle and/or protein damage, the cell will produce abundant autophagosomes 
leading to eventual death of the cell [73, 80].    
This dual behavior allows autophagy to illicit tumor suppressor and tumor promoter 
functions depending on the circumstances [79].  A cell that is under increased stress via ROS can 
utilize autophagy to remove damaged material allowing it to return to a normal state [48, 73, 79, 
81].  However, consistent exposure to ROS can lead to mutations creating a more aggressive cell 
type [48, 73, 79, 81].  Autophagy can assist in the cells’ survival when it otherwise may not be 
able to tolerate the stress.   Further, cancer cells can utilize autophagy to produce nutrients in an 
environment that is otherwise depleted [48, 73, 79].    
The third major programmed cell death mechanism is known as necroptosis [72].  This 
mechanism has only recently been established [82].  Prior to this, the phenomenon was 
considered part of a nonprogrammed event known as necrosis.  Necrosis involves the loss of 
plasma membrane integrity leading to cytoplasmic contents entering the microenvironment [72].  
This phenomenon can be induced by elevated levels ROS.  The mechanism is considered 
nonprogrammed since it is not cued by a specific signaling pathway.   Characteristics or 
necroptosis are similar to necrosis; however, has been shown to be regulated by RIP proteins [72, 
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83].  RIP proteins create a scaffold called a ripoptosome that provides the signals that lead to 
membrane permeabilization [83].   
An iron mediated cell death pathway was recently discovered called ferroptosis which 
can be induced by inhibition of the Ras pathway [3].     Inhibition of the Ras pathway was found 
to increase ROS levels thus promoting membrane permeability and mitochondrial stress [3, 84].   
This mechanism, although intriguing, is yet to be fully understood.  Only two articles are 
currently available on this mechanism; thus there is more to elucidate about the pathway [3, 84]. 
 
Concluding Remarks 
The overall focus of our project was to further understand the role of endometriosis in the 
development of ovarian cancer.  We divided this study into two components. One section 
focused on establishing an in vitro model to study endometriosis.  This involved the development 
of a novel immortalized epithelial endometriotic cell line and proteomic profiling in comparison 
to other well-established ovarian cell line subtypes.  The second section focused on investigating 
how high levels of iron (seen in endometriotic lesions [13, 35, 85]) would alter growth and 
behavior of normal gynecological and ovarian cancer cell types.   We wanted to determine if iron 
could increase cell growth in “normal” cell types which would be suggestive of acquisition of a 
more aggressive phenotype.   In contrast to expected results, we found that iron was detrimental 
to cell types harboring Ras mutation/overexpression.  This directed us to focus on the cell 
signaling pathways and cell death mechanisms induced by iron treatment.  We present herein the 
characterization of iron treatment in gynecological cells.  The hypothesis and specific aims 
addressed in this thesis are described below.  
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Specific Aims 
The goal of our studies was to understand the role of iron in gynecological cell types.   We 
hypothesized that cells with overexpressed or mutated Ras expression would be sensitive to iron 
treatment.  Moreover, we hypothesized that continuous iron treatment would induce “normal” 
cells to grow, leading potentially to carcinoma-like characteristics.  We addressed these 
hypotheses in the following aims.    
 
Development and Characterization of a Novel Endometriotic Cell Line (Chapter 3) 
Aim 1: Characterize primary endometriotic cell lines 
1.1 : Determine if cells are stromal or epithelial  
1.2 : Assess markers of growth, survival, cell cycle, and EMT in relationship to 
existing ovarian cell types 
Aim 2: Immortalize and establish a novel endometriotic cell line 
 2.1: Immortalize cells 
 2.2: Characterize the immortalized cells to confirm immortalization and the retention of 
similar proteomic profile expressed in primary cells 
Aim 3: Determine the role of autophagy in endometriotic cell survival 
 3.1 Inhibit autophagy and determine the survival capacity of endometriotic cells  
 
Iron modulates cell survival in a Ras- and MAPK-dependent manner in ovarian cells (Chapters 
4, 5, and 6) 
Aim 1: Determine the influence of iron in gynecological cell types 
 1.1: Assess changes in cell behavior (growth, cell survival, migration, wound healing) 
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           1.2: Determine the form of cell death induced by iron treatment 
           1.3: Effect of iron in an anoikis-induced environment 
Aim 2: Validate that Ras- and MAPK- markers are crucial for iron-induced cell death 
           2.1: Use of inhibitors to reverse cell death 
           2.2: Investigate the role of iron regulatory pathways to identify the dependence on Ras 
Aim 3: Identify cell signaling pathways downstream of Ras/MAPK that are involved in iron-
induced cell death 
 3.1: Determine the role of mitochondrial in iron-induced cell death 
 3.2: ROS activity in iron-induce cell death 
 
 
Overall Studies 
Chapter 3 concerns the development and characterization of a novel endometriotic cell 
line.  The work presented in Chapter 3 represents unpublished data (Bello et al., unpublished 
data) performed in collaboration with the laboratory of Dr. Idhaliz Flores.    Chapters 4, 5, and 6 
focus on the role of iron in gynecological cell growth and function.   The data presented in 
Chapter 4 represents the published work entitled “Iron modulates cell survival in a Ras- and 
MAPK- dependent manner in ovarian cells”  in the journal Cell Death and Disease (2013).   
Chapter 5 presents in progress studies that will contribute to a yet untitled anoikis paper.  Finally, 
Chapter 6 represents the follow-up to the work presented in Chapter 4 which will be submitted in 
the near future.    
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Chapter 2 
 
Materials and Methods 
 
Cell Lines     
Serous carcinoma cell line, HEY and normal surface ovarian epithelial cells (T80) were provided 
by Dr. Gordon Mills at MD Anderson Cancer Center, Houston Texas.  Cells were maintained in 
RPMI media with 8% Fetal Bovine Serum (FBS) and penicillin/streptomycin.   T80 + H-Ras and 
T80 + K-Ras cells were also provided by Dr. Gordon Mills.  These cells were also maintained in 
RPMI media with 8% FBS and penicillin/streptomycin.  The endometrioid carcinoma line 
(TOV112D) was purchased through ATCC, Manassas Virginia and the clear cell carcinoma cell 
line (TOV21G) provided by Dr. Johnathan Lancaster at Moffitt Cancer Center, Tampa Florida.   
Both TOV112D and TOV21G were maintained in a 1:1 mixture of Medium 199 and MCDB131 
with 8% FBS and penicillin/streptomycin.  HES cells were provided by Dr. Douglas Kniss at 
Ohio State University, Columbus Ohio.   HES cells were maintained in DMEM with 8% Fetal 
Bovine Serum (FBS) and penicillin/streptomycin.  All cell lines reported in the following work 
have been tested and confirmed mycoplasma negative along with STR profiled with the 
exception of HES cells.  HES cells were reported to contain markers of HeLa cells [4].  
Experiments were performed only with cells under a passage of 20.   
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Immortalization of primary endometriotic cells   
Primary endometriotic cells were provided by Dr. Idhaliz Flores at Ponce School of Medicine, 
Puerto Rico.   The cells were maintained in 1:1 mixture of Medium 199 and MCDB131 with 8% 
FBS and penicillin/streptomycin along with insulin/transferrin/selenium (ITS).  We utilized large 
T antigen to immortalize the primary cells.   We obtained large T antigen pBABE-puro vector 
from Addgene.   We generated retroviral particles utilizing HEK293T cells.  These cells were 
transfected with pCGP and pVSVG vector.  Collections of retroviral media were collected at 48h 
and 72h post-transfection.  These particles were filtered (removal of HEK293T cells) and then 
used to infect the primary endometriotic cells.  After infection, cells were treated with puromycin 
(2.5 µg/mL) to select for positively infected cells.   We isolated 6 colonies that we expanded and 
validated for future use.     
 
Isolation of genomic DNA  
Genomic samples were obtained using the DNeasy blood and tissue kit purchased from Qiagen. 
     
Cloning of HO-1 
 RNA was extracted from T80 cells utilized an RNeasy kit from Qiagen.  The samples were then 
quantified using Nanodrop (purchased from Thermo Scientific).   RT-PCR was performed 
utilizing the primers below (NCBI NM_002133.2): 
Forward primer: 5′-GGAATTC-ACCATG-GAGCGTCCGCAAC-3′ 
Reverse primer: 5′-G-GAATTC-TCA-CATGGCATAAAGC-3′  
Samples were run with PCR conditions of 48 
o
C 30mins, 94 
o
C for 2 minutes, 40 cycles of 
denaturation at 94 
o
C for 1 min, annealing at 60 
o
C for 1 min, extension at 68 
o
C for 5 min and a 
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final extension of 72 
o
C for 15 minutes.   This PCR product was cloned into a pBabe-puro 
pTOPO vector (obtained via Invitrogen).  To confirm positive clones, EcoRI-HF (from NEB 
Biolabs, cuts at 5'..,G/AATTC...3' and 3'...CTTAA/G...5") was utilized to digest the plasmid to 
confirm proper insertion.  The primers above are separated by dashes to distinguish between the 
EcoRI site, start codon, and HO-1 specific region.    The insert was gel purified and the vector 
dephosphorylated utilizing Antarctic acid phosphatase from NEB.  After this, the insert was 
ligated to the dephosphorylated vector using T4 Quick DNA ligase (from NEB).  Positive clones 
were sequenced by the Moffitt Cancer Center, Molecular Biology Core to ensure no mutations 
occurred in the HO-1 sequence.  Once confirmed, the plasmid was made in high quality and 
quantity via Maxi Large Plasmid preparation (purchased by Qiagen) to utilize for downstream 
applications. 
 
PCR-sequencing  
Genomic sequencing of PIK3CA and K-Ras in the immortalized endometriotic cells was carried 
out via the following conditions:   94 C for 2 minutes, 40 cycles of 94 
o
C for 1 min, 45 
o
C for 1 
min, 68 
o
C for 1 min and a final extension of 72 
o
C for 10 minutes.   The PCR samples were 
identified on a 1.5% agarose gel and gel purified with a Qiagen gel purification kit.   Purified 
PCR sample was sequenced by the Moffitt Cancer Center, Molecular Biology Core.  Primers 
below are specific for PI3KCA exons 9 and 12 (NCBI NM_006218.2) and K-Ras exon 1, codon 
12 and 13 (NCBI NM_004985.3).   
PI3KCA Exon 9:  
Forward primer: 5′-GAATCCAGAGGGGAAAAA-3′ 
Reverse primer: 5′-CCATTTTAGCACTTACCTG-3′  
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PI3KCA Exon 12: 
Forward primer: 5′-TTGATGACATTGCATACATTCG -3′ 
Reverse primer: 5′-ACCTGTGACTCCATAGAAA-3′  
 
K-Ras:  
Forward primer: 5′-GCCTGCTGAAAATGACTG-3′ 
Reverse primer: 5′-GTTGGATCATATTCGTCCA-3′  
 
Generation of stable cell lines  
We generated retroviral stable HO-1 expression in T80 cells.  As with primary cell 
immortalization, we utilized HEK293T packaging cell to generate virus particles.   pCGP and 
pVSVG vectors (containing viral components: gag and pol in pCGP and env in pVSVG) 
(purchased from Clonetech) using Fugene HD (Roche) were again utilized and 48 hour and 72 
hour post-transfection.  Retroviral particles were collected and placed in wells to infect the 
desired cells (T80).  This process was similarly used for stable knockdown studies of ATG5.  A 
pSUPER control and two unique ATG5 shRNA (with coding regions of 5′ GGC ATT ATC CAA 
TTG GTT TA 3’ and 5′ GCA GAA CCA TAC TAT TTG CT 3’ labeled as H2 and H7 
respectively (targeting exon 4 and 3 respectively of ATG5)).  These shRNAs were created by Dr. 
Xiao-Feng Zhu at the State Key Laboratory of Oncology in South China.   Endogenous ATG5 
was knocked down utilizing these shRNAs in T80, HEY, TOV112D, and TOV21G cell lines.  
Once infected, the cells were treated with puromycin (2 μg/ml for HEY, 1 μg/ml for T80, 2 μg/ml 
for TOV112D, and 2 μg/ml for TOV21G) to allow for selection of infected cells (48 hour 
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treatment with puromycin).    Knockdown of ATG5 expression in the stable cell lines were 
validated via real-time PCR and western analysis. 
   
siRNA knockdown studies   
Cells were seeded at 325,000 per 6 well plate and left to adhere overnight.   The following day 
cells were transfected with one of the following siRNA:  NRF2 (L-003755-00), ATG6/beclin-1 
(L-010552-22), ATG7 (L-020112-00), hVps34 (L-005250-00), H-Ras (L-004142-00), K-Ras (L-
005069-00), HSP70 (L-021084-01), or non-targeting ON-TargetPLUS control (D-001810-10) 
along with  Dharmafect I obtained from ThermoScientific.  The transfection process started with 
removal of complete media and addition of warm (37 
o
C) serum free media.   Cells were placed 
in incubator while siRNA cocktail was assembled (100 µL serum free media, 5 µL of a 20µM 
siRNA stock, and 4 µL of Dharmafect).   This was added drop-wise to wells and left to incubate 
for 3 hours.  Complete media was overlayed after 3 hours and left overnight.    The following 
day, media was removed and fresh complete media was added.  Cells were allowed to recover 
for 3 hours and then a 2
nd
 transfection was performed following the same process.   The 3
rd
 day, 
media was removed and replaced with fresh complete media and recovered for 3 hours.  After 
the recovery phase, cells were treated or reseeded (followed by treatment).   All knockdowns 
were validated by western analysis; NRF2 knockdown was further validated with qPCR. 
 
Protein isolation, SDS-PAGE, and western blot analyses 
 All cells following treatment had media removed and were washed with PBS.   PBS was 
removed and cells were lysed with RPPA lysis buffer for 1 hour on ice.  Cells were then scraped, 
lysate collected, and spun down to remove cell pellet.  Protein lysate concentration was 
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determined utilizing a BCA assay (Thermo Scientific).  BCA is a colorimetric assay to determine 
concentration of protein.   Dilutions were prepared based on BCA readings and prepared for a 
total volume of 50 µL.  10 µL of 6x SDS loading buffer was then added to the samples.  All 
samples were run on 8, 10, or 12 % polyacrylamide gels along with molecular weight markers.  
Samples were run at 100 volts for 2.5 hours.  The gel was transferred using a semi-dry apparatus.  
PVDF membranes were activated utilizing 100% methanol and used to transfer gel contents on.  
The transfer process lasts 2 hours at 0.11 Watts for one membrane.  Membranes were then 
washed with 1x TBST for 10 minutes followed by a blocking period of one hour.  We utilized 
5% milk in TBST for the blocking process.  Following blocking, cells were briefly washed with 
1x TBST and primary antibody was applied overnight.  Membranes were then placed on a shaker 
in a 4 
o
C cold room for overnight blocking.  The following day, primary antibody solution was 
removed and the membrane washed with TBST for 1 hour (changing out the wash every 15 
minutes).   Following the wash, secondary antibody was applied for 1 hour (secondary antibody 
was added in milk).  The concentration of secondary was dependent on the primary antibody.  
After secondary treatment, the membrane was washed with TBST for 1.5 hours (changing the 
wash every 15 minutes).  After washing, the membrane was treated with ECL luminescent 
detection reagent and developed utilizing x-ray film.   After developing, membranes were 
regenerated for an hour utilizing stripping buffer.  Afterwards, cells were washed, blocked, and 
primary was applied for another antibody.  Primary antibodies are summarized below in Table 1. 
 
RNA isolation and qPCR    
Total RNA was extracted utilizing the RNeasy Mini Kit from Qiagen.  We utilize the one-step 
RT-PCR master mix obtained from Applied Biosystems to determine mRNA levels of HO-1 
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Table 1: List of primary antibodies used for thesis.  
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 (HMOX, Hs01110250_m1) and NRF2 (NFE2L2, Hs00975961_g1). All results were normalized 
using β-actin and then by comparing treated cells with untreated cells (or HO-1 expressing cells 
to vector control cells).  The fold changes in RNA were calculated using the formula 2
−ΔΔC
T . 
 
Immunofluorescence  
Autoclaved glass cover slips were placed in 6-well plates and cells were seeded.  Cells were 
allowed to grow on top of the cover slips overnight prior to treatment.  For EGFP-LC3 (obtained 
from Addgene), cells were transfected and treated the following day (following a 3 hour 
recovery). 
   
Transmission electron microcopy  
Cells were grown to confluence in 100mm dishes and treated with FAC at 0, 6, 18, and 24 h.  
The samples were fixed in 0.1 M phosphate buffered 2.5% glutaraldehyde overnight, followed by 
1 hour in buffered 1% osmium tetroxide, dehydrated in a graded series of acetone, and then 
embedded in LX 112 epoxy resin.  Thin sections obtained from blocks of the samples were 
stained with 8% aqueous uranyl acetate and Reynold’s lead citrate.  These samples were viewed 
and recorded via a FEI Morgagni 268D (FEI Company, Inc. Hillsboro, OR, USA) TEMs were 
imaged at multiple magnifications.  Edward Haller (Department of Integrative Biology, College 
of Arts and Sciences, University of South Florida) carried out fixation, generation of slider, and 
imaging of all samples.     
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Cell cycle analysis  
Upon completion of experimental treatment, cells were trypsinized and spun down.  Cells were 
suspended gently with cold PBS and then gradually vortexed 9 mL of 70% ethanol (in PBS).  
Samples were stored overnight in -20 
0
C.   The following day, samples were spun down and then 
washed with 2 ml cold PBS.  The PBS was removed and 500 µL of Propidium Iodide (PI) mix 
was added (20% Triton X, 1.6mg RNase, 500 µg/µL Propidium Iodide (PI).  This solution was 
stored at room temperature for 15 minutes in the dark.  Samples were read via flow cytometry at 
the College of Medicine University of South Florida.    
 
ATP viability assay 
 A cell titer glo assay as utilized to detect ATP levels.   Cells were seeded in 96 white opaque 
plates.  HEY, T80, T80 + H-Ras, T80 + K-Ras were seeded at 2500 cells/well and TOV112D 
and TOV21G at 5000 cells per/well.  After treatment, media was removed and wells washed 
with PBS.  ATP was detected utilizing the ATP viability kit purchased from Promega.   Readings 
were measured via luminescence detection (reported as relative light units, RLU).   
 
Wound healing assay 
 A cytoselect 24-well plate (purchased from Cell Biolabs) was utilized to perform wound 
healing.  The assay consisted of a 24 well plate with inserts that prevent cells to grow in the area.  
Cells were seeded at 250,000 (T80), 500,000 (TOV112D, TOV21G, and T80 + H-Ras), 400,000 
(T80 + K-Ras), and 200,000 (HEY) cells.  These numbers were optimized to ensure cells were 
confluent upon treatment.  Once treatment was added, the inserts were removed and cells were 
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allowed to grow in the vacant area.   After completion of treatment period, cells were imaged and 
stained to determine growth of wounds.    
 
Colony formation assay  
Cells were seeded at 500 cells/well in a 6 well plate and allowed to adhere overnight.   The 
following day the wells were treated and allowed to grow for 2 weeks.  Upon completion, cells 
were stained with crystal violet. 
   
Lysosome detection  
Lysotracker was utilized both for immunofluorescence and flow cytometry.  For 
immunofluorescences, cells were seeded on glass cover slips in 6 well plates.  The following day 
cells were given desired treatment.  One hour before the end of treatment, cells were treated with 
Lysotracker Red (Invitrogen).  Media was removed and pre-warmed media containing 75nM 
Lysotracker Red was added.  Cells were placed back in the 37 
o
C incubator for 1 hour.   A 
similar process was carried out with flow cytometry utilizing 75 nM Lysotracker Green.  
Adherent cells were trypsinized and combined with the collected media containing the non-
adherent population.   
 
Mitochondrial detection  
Cells were seeded on glass cover slips in 6 well plates at 250,000 cells/well.  The following day 
cells were given desired treatment.  1 hour before the end of treatment, cells were treated with 
Mitotracker Red-CMXROS (Invitrogen).  Media was removed and pre-warmed media treated 
with 250nM Mitotracker Red CMXROS was added.  Cells were placed back in incubator for 1 
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hour. After treatment, the media was removed, cells washed with PBS, fixed in 4% 
formaldehyde/PBS for 30 minutes, followed by two PBS washes. 
 
Lactate dehydrogenase assay (LDH)  
Cells were seeded in 96 well plates at 2500 cells per/well.  Cells were placed in media with only 
1% FBS.  Cells were treated the following day for desired treatments.  Upon completion of 
treatment, plates were spun down and 100 µL of media was collected from each well and 
transferred to a new 96 well plate.   100 µL of LDH reaction mixture (purchased from Fisher 
Scientific) was added to the wells.  The plate was incubated at room temperature for 30 minutes 
and then read on a plate reader with a wavelength of 490 nm.  The relative toxicity was 
determined by subtracting background from media only controls (0.1% FBS). 
 
Annexin V/PI apoptosis assay  
The Annexin V/ PI staining was purchased via Calbiochem.  After treatment of cells, media was 
collected and transferred to a conical tube.  Samples were trypsinized and mixed with the 
collected media.  Samples were spun down and the pellet retained.   Samples were suspended in 
500µL of PBS and transferred to an Eppendorf tube.  Samples were treated with 10µL binding 
reagent followed by 1.25 µL of Annexin V FITC.  The samples were then incubated at room 
temperature for 15 minutes in absence of light.   Samples were spun down and supernatant 
removed and pellet suspended with 500 µL of binding buffer.  10 µL of PI was added and 
samples were incubated on ice for 30 minutes (in the dark).   Samples were analyzed via flow 
cytometry at the College of Medicine University of South Florida with the assistance of Dr. 
Karoly Szekeres.  
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Chemical treatments  
Chloroquine (CQ) (Fisher Scientific, Pittsburgh, PA, USA) (12.5 or 25 μM) was dissolved in 
tissue culture-grade water. Ferric ammonium citrate (Fisher Scientific) was utilized between 
5μM to 10mM and dissolved in tissue culture-grade water or PBS. Deferoxamine mesylate 
(DFO) (Sigma-Aldrich, St. Louis, MO, USA) was used between 1 nM to 250 μM, and dissolved 
in tissue culture-grade water. Ferrostatin (no. 9065366, C15H22N2O2, ChemBridge, San Diego, 
CA, USA) was used at 100 μM and dissolved in dimethylsulfoxide (DMSO). U0126 and 
LY294002 were obtained from Cell Signaling Technology (Danvers, MA, USA) and used at 
doses of 10 μM and 75 μM, respectively (dissolved in DMSO). Ru360 (Fisher Scientific) 
dissolved in de-oxygenated tissue-culture grade water was utilized at a final concentration of 
10µM. 
 
Senescence assay   
After treatment, media was removed and washed with PBS.  A β-galactosidase senescence assay 
was purchased via Cell Signaling Technology to allow detection of senescence.  After a PBS 
wash, 1 mL of fixative was added to each well for 10 minutes.  Fixative was removed and cells 
were washed twice with PBS.  1 mL of β-galactosidase staining solution was then added and 
incubated at 37 
0
C overnight.   The following day the plates were observed under a light 
microscope for the detection of blue staining.  The stain is indicative of β-galactosidase a marker 
of senescence.   
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Cell viability  
Cells were seeded at 5000 cells/well (IE, HES, TOV112D, and TOV21G) or 2500 cells/well 
(T80 and HEY) in 96-well plates.  Cells were left to adhere overnight and the following day 
treated as needed.   Once treatments finished, cells were stained with crystal violet.  Once dry, 
wells with crystal violet were treated with Sorenson’s buffer to dissolve stained samples.  
Samples were quantified using a plate reader at 570 nm wavelength.    
 
ROS detection assay  
Cells were seeded at 5000 cells/well (TOV112D, and TOV21G) or 2500 cells/well (T80, T80 + 
H-Ras, and HEY) in 96-well plates.  Cells were allowed to adhere and grow overnight.  The 
following day, the media was removed from the wells and they were washed with 100 µL PBS.  
PBS was removed and replaced with warm PBS treated with H2DCFDA dye at a 10 µM 
concentration.  Cells were incubated with dye for 30 minutes at 37 
o
C.  Following staining, PBS 
with dye was removed and replaced with media containing desired treatments (FAC) or with 100 
µM hydrogen peroxide (to serve as a positive control).   In the presence of ROS, H2DCFDA 
becomes cleaved creating fluorescence signal.  Signal was measured via a plate reader with an 
excitation wavelength of 485 nm and an emission wavelength of 530 nm.    
 
Anoikis assay   
Poly-HEMA was dissolved in 95% ethanol to generate a 20 mg/mL poly-HEMA stock solution.  
Poly-HEMA was dissolved overnight on a shaker.  Poly-HEMA solution was filtered and then 
used for cell treatments.   100 µL of solution was added to each 96 well plate and 1mL for each 6 
well plate (to ensure full coverage of the well).  Plates were allowed to air-dry in a biosafety 
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cabinet until ethanol evaporated.  Another coat of poly-HEMA was then added and allowed to 
dry to ensure full coating.  Plates were left to dry overnight followed by two washed with PBS to 
remove any remaining ethanol or particulate.   Cells were treated upon seeding.    
 
Statistical analysis   
All experiments presented were carried out in replicates as specified in the figures.   We utilized 
error bars to represent the standard deviation based on P-values (a standard student’s t-test) 
generated using Prism software.   NS symbolizes non-significant p-values (p>0.05), * represents 
p<.05, ** represents p<.01, and *** represents p<.0001. 
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Chapter 3 
 
Development and Characterization of a Novel Endometriotic Cell Line 
  
Introduction 
Endometriosis is a debilitating disease that affects millions of women every year [37].   
Patients with endometriotic lesions frequently have debilitating pain and a risk of becoming 
infertile [86].   Further, there is evidence of increased risk for epithelial ovarian carcinoma [36, 
49, 87]. Though modern treatment strategies are in place to diminish and remove the lesions, 
there still remains a serious risk to patients diagnosed with the disease.   Studies have 
demonstrated a correlation between endometriosis and presence of clear cell/endometrioid 
ovarian carcinomas [13, 15, 36].  Association of endometriosis to ovarian cancer is classified by 
identification of the carcinoma and endometriotic lesion in the patient region [12, 13, 68].  Since 
cancer is more invasive, endometriosis tissue is often overlooked.   As a result, current statistics 
may underestimate the occurrence of ovarian cancer due to endometriosis.   Atypical 
endometriotic lesions are correlated with an increased risk of ovarian cancer development [14, 
33, 38].    Multiple groups have shown that the transition from endometriosis to ovarian cancer is 
mediated by the development of atypical endometriosis [15, 33, 38, 50].  Atypical endometriosis 
is correlated with the presence of metaplasia, hyperplasia, and cytological atypia [33, 38].  
Interestingly, atypical endometriotic lesions contain mutations in HNF1β [59], ARID1a loss of 
heterozygosity (LOH) [14, 15], and decreased levels of progesterone [14, 15, 18, 33, 38, 51, 59].  
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These atypical lesions contain multiple aberrations including activating mutations in the catalytic 
subunit of PI3K (PIK3CA) in exon 9 and exon 20, deletion of ARID1a (LOH i.e. loss of function 
of an allele on one chromosome), as well as overexpression of HNF1β (a transcription factor 
involved in increased metabolism) [14, 15, 17, 18, 59].   Further, studies have shown mutations 
such as p53 inactivation [12], PTEN deletion and/or inactivation [17, 18], and  increased K-Ras 
expression [60, 61].  These mutations are considered critical for the transition from 
endometriosis to ovarian cancer [12, 14, 60, 61].   One study has even suggested that K-Ras may 
be a key marker involved in the transition from atypical endometriotic lesions to clear cell 
ovarian carcinomas [61].  However, since these studies utilized patient samples from advanced 
stage IV ovarian cancers, the invasive nature of the cancer tissue may have hindered detection of 
endometriotic lesions.   
   The transformation from endometriosis to ovarian cancer is a poorly defined process.  
One hypothesis argues reactive oxygen species (ROS) and inflammatory responses within the 
endometriotic cyst may promote this transition to cancer [13, 35, 88, 89].  As discussed in 
Chapter 1, these endometriotic cysts, also known as “chocolate cysts,” are filled with “old blood 
components” including iron-rich heme.  Iron inside the cyst can lead to transformation of the 
surface of the ovary to an ovarian clear cell like morphology [13].  Cysts may release free radical 
iron, generating ROS throughout the microenvironment leading to increased inflammation and 
cell stress [13, 35, 90].  Iron production of ROS through Fenton chemistry interactions with ROS 
producing enzymes (such as NADPH, NOX, and LOX), leads to free radicals that can cause 
DNA and mitochondrial DNA damage [13, 35, 71, 90].  While this stress often leads to cell 
death, consistent exposure to ROS may lead to mutations favored for tumorigenesis [13, 35, 90].    
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The use of patient samples to correlate endometriosis and ovarian cancer has been 
limiting.  As mentioned above, the majority of patient studies derive from cases with advanced 
stages of ovarian cancer. Thus, these advanced stage ovarian cancer specimen studies could 
potentially prevent identification of endometriotic lesions leading to an underestimation of 
associated risks.  Secondly, since the process of lesion removal is quite invasive, the patients 
frequently prefer to undergo non-surgical treatment strategies (i.e. hormone therapy) [45, 51, 52]. 
As a result, the patient sample size is often limited.  In addition, endometriosis may be 
asymptomatic until it has reached an aggressive and harmful stage.  Other research constraints in 
the field of endometriosis are the limitations with model organisms. Since the development of 
endometriosis necessitates the presence of an estrus cycle, a system that occurs only in primates, 
animal models which utilize rodents (i.e. mice and rats) are thus not ideal experimental model 
organisms [91, 92]. Recently, however, a validated mouse model for endometriosis has been 
developed [93-95] which involves the implantation of gynecological tissue of a donor mouse into 
a syngeneic recipient mouse [94].  This implanted tissue eventually develops into endometriotic-
like lesions in the peritoneal cavity with characteristics similar to those that develop in women 
[91, 92]   
Currently, the most accepted animal models for the study of endometriosis are baboons 
and rhesus monkeys [91, 92, 96].  These primates undergo an estrus cycle similar to humans and 
are ideal for endometriosis studies.  However, baboons present difficulties in experimentation 
due to their time to reproductive maturity, size, and cost [91, 92, 96].  Further, endometriosis in 
baboons may take several years to develop with only a portion of the animals (<5%) even 
developing endometriosis [91].  In vitro research studies based on the use of cell lines also are 
faced with limitations. The use of primary cells has limitations with regards to both life span 
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(passage number) and availability (lack of patient samples from which to derive the primary 
cells).  While a limited selection of immortalized endometriotic cell lines are available for study, 
their origins and purity have recently come under question (see Table 2) [4].   For example, some 
endometrial cell types (i.e. HES, EEC) that have been utilized by many prominent endometriosis 
laboratories have been recently identified to be other cell types (i.e. HeLa and MCF7, 
respectively) [4]. Moreover, several published endometriotic cells have not been fully validated 
to confirm either stromal or epithelial origin. None of the published cell lines have been Short 
Tandem Repeat (STR) profiled publicly [4].   
This lack of cells is not without reason.  One dilemma with isolating ectopic 
endometrium for cell line development is its diverse cellular composition. Indeed, the normal 
endometrial tissue termed “eutopic” (derived from the endometrium) while the cysts termed 
“ectopic” (growths outside the endometrium) [52]  consists of a mixture of stromal and epithelial 
cells.  In this respect, we would be required to isolate epithelial cells from the total cell 
population. Lastly, endometriotic cysts are not monoclonal in nature, suggesting the isolation of 
a selected subpopulation of cells may not represent the cysts in its entirety [97]. Due to a dire 
need to develop a fully validated and immortalized endometriotic cell line, we attempted to  
 
 
 
 
 
 
Table 2: Table of endometriosis related cell lines. 
Table provides description of endometriosis cell types available in literature 
along with their origin, characteristics, and reported problems [4-8]. 
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develop such a cell line derived from primary endometriotic cells.  We obtained two primary 
endometriotic cell lines (called Primary C and Primary D) from the laboratory of Dr. Idhaliz 
Flores (Ponce School of Medicine, Puerto Rico) which was isolated from endometriotic cysts of 
a patient. Herein, we attempt to develop a novel endometriotic cell line that we characterize for 
specific markers (i.e. stromal, epithelial, EMT, tumor suppressor, cell growth, and cell cycle 
regulators) prior to and following retroviral infection with SV40 large T antigen.   It has 
previously been observed that endometriotic cells express a honeycomb morphology along with  
expression of epithelial marks (cytokeratin) and the absence of stromal characteristics (vimentin) 
[5].  We believe that this novel endometriotic cell line (termed “IE” cells) will contribute toward 
future in vitro studies of endometriosis. 
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Figure 8:  Cell profile of primary endometriotic cells. 
Continued on following page.     
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Figure 8:  Cell profile of primary endometriotic cells. 
Primary endometriotic cells were compared to endometrioid, clear cell, 
adenocarcinoma, and serous carcinoma cell lines to determine the expression 
patterns of tumor promoters (EVI1, RON, EGFR, SnoN, AKT), tumor 
suppressors (TGFβRII, Smad2/3,PTEN), autophagy markers (ATG5, ATG7, 
beclin-1, hVps34), epithelial markers (E-cadherin), and Stromal Markers (N-
cadherin, vimentin).    
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Results 
Basal protein expression analyses of primary endometriotic cells reveals markers of epithelial 
and stromal cells 
 Since the characteristics of the primary C and D endometriotic cells have not previously 
been delineated, we performed an in-depth protein analysis of markers important in cell growth, 
migration, regulation, and survival.  The primary cells were derived from endometrial tissue of a 
patient with endometriosis.  We wanted to investigate if the protein expression of primary cells 
(EMT, growth, cell cycle markers, tumor suppressors, autophagy proteins) were similar to that of 
any available gynecological cell line (see Figure 8). Thus, we performed western blot analyses of 
primary endometriotic cell C and D together with a large array of ovarian carcinoma cell lines 
(see Figure 8).  The gynecological cancer cell lines included endometrioid ovarian cancer cell 
line (TOV112D), clear cell ovarian cancer cell line (TOV21G), endometrial adenocarcinoma 
(MFE296, MFE319, AN3-CA, KLE, HEC-1A), and serous epithelial ovarian cancer (OVCAR8, 
HEY, SKOV3) cell lines (see Figure 8).  Along with these cell lines, a normal immortalized 
ovarian surface epithelial cell (T80) was also analyzed.  When we carried out this cell profile, all 
of the cells were tested to be mycoplasma-negative and STR profiled (data not shown).  This is 
of importance as recent reports revealed that multiple gynecological cancer cell lines have been 
mis-identified or contaminated by rapidly growing cell lines including HeLa [4].  Fortunately, 
one study performed STR analysis on HEC-1A, KLE, and AN3-CA and have found they all 
contain a unique profile [4].  In addition, we have validated our HEY, TOV21G, and TOV112D 
cell lines via STR profiling and authenticated their identity (data not shown).   
  We next surveyed an array of proteins critical in cell growth, regulation, and survival to 
determine global expression patterns.  First, we assessed whether the cells were epithelial or 
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stromal in origin. We investigated the expression of epithelial markers including E-cadherin as 
well as stromal markers including N-cadherin and vimentin (see Figure 8).  Next, we assessed 
the proliferative capacity of the primary cells relative to ovarian cancer cell lines. To address 
this, we investigated the expression of tumor promoters including EVI1 and SnoN/SkiL (a TGFβ 
co-repressors amplified at the 3q26.2 locus in ovarian cancers) (see Figure 8) [98].  We then 
assessed the expression of tumor suppressors including p53, PTEN, and Smad2/3 (see Figure 8).  
We also assessed markers of autophagy (ATG5, ATG7, beclin-1) in the primary cell types 
relative to ovarian cancer cells since some studies have implicated autophagy in influencing cell 
survival, possibly endometriotic and endometrial cell survival (see Figure 8) [78, 81].  
As shown in Figure 8, the primary cells expressed tumor suppressors PTEN and Smad2/3 
with undetectable levels of the tumor promoters EVI1 and SnoN/SkiL. We were unable to detect 
E-cadherin expression in both the primary C and D cell lines although we did detect low level 
expression of the stromal markers, vimentin and N-cadherin. These results suggest that the 
primary cell lines contain characteristics of stromal cells.  Indeed, visual observation of the 
primary cells under the light microscope clearly demonstrates the presence of two distinct cell 
types, one with honeycomb morphology representative of an epithelial-like endometriotic cell 
population with another cell type of a more elongated, fibroblast-like morphology (data not 
shown).  Furthermore, after several passages in culture, the population shifted greatly in favor of 
the stromal-like morphology suggesting that the stromal-like cell population were capable of 
outgrowing the slower growing epithelial population (data not shown).  In addition, we noted 
that the cell line growth capacity slowed markedly after 10 passages in culture, which hindered 
long-term studies.  
 
44 
 
Retroviral infection with SV40 large T antigen extends lifespan of IE cells  
Due to the limited passage number inherent with the primary cell line, we proceeded with 
immortalization.  In brief, immortalization can occur through the expression of large T and small 
T antigens thus leading to inactivation of p53 [99, 100].  The expression of hTERT is also 
required to prevent the shortening of telomeres which would eventually lead to cellular 
senescence [101].  While these two agents are classical markers of cell line immortalization, a 
number of other markers are considered important in immortalizing primary cells (as well as in 
tumor development) including Ras mutations and activation of the PI3K pathway which leads to 
increased cell proliferation [18, 61, 93, 95, 99, 101].   
 In our approach to immortalize the endometriotic primary cells, we infected both 
primary C and primary D cells with retrovirion particles harboring the SV40 Large T Antigen 
along with a separate batch of cells infected with retrovirion particles harboring hTERT. As a 
comparison, the immortalization of the normal surface ovarian epithelial cell, T80, previously 
developed by Dr. Liu (MD Anderson Cancer Center) was performed in a similar fashion [101]. 
Since T80 and our primary endometriotic cells are both of gynecological origin, we believed a 
similar approach to immortalization would be successful.   Following retroviral infection, the 
cells were successfully maintained in the absence of ITS (insulin-transferrin-selenite) [101].  
Positive cells were selected using the puromycin selective marker.  hTERT infection 
resulted in high levels of toxicity resulting in the inability to maintain the cell line.  However,  
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Figure 9:  Cell profile of immortalized endometriotic cells. 
Continued on following page.     
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several SV40 large T antigen clonal pools were successfully obtained.  Colonies were selected 
based on the epithelial-like morphology and maintained for a month to ensure stable expression 
Figure 9:  Cell profile of immortalized endometriotic cells 
A/B. Primary D endometriotic cells were retrovirally infected with SV40 large 
T antigen and selected with puromycin.   Individual colonies were picked and 
grown in culture for one month.  Lysate was collected from each colony and 
assessed for expression of large T antigen.  Other markers were used to assess 
change in cell expression due to SV40 large T antigen (EVI1, SnoN, and 
autophagy markers) as well as confirmation of positive selection of epithelial 
cells (absence of vimentin). Expression of p53 indicates inactivation via 
expression of large T antigen. C. Confirmation of absence of vimentin and 
presence of cytokeratin-3 (Cy-3) (epithelial marker) was performed via 
immunofluorescence.  T80 cells serve as a positive control for Cy3 and 
SKOV3 a positive control for vimentin.   
47 
 
of large T antigen.  Validation of SV40 large T antigen expression in all colonies was performed 
via western blot analyses (see Figure 9).  We observed decreased expression of the stromal 
marker vimentin (relative to the primary cells), indicating that we successfully selected for the 
epithelial-like population of endometriotic cells (see Figure 9).  To confirm the epithelial nature 
of the selected populations, we performed immunofluorescence staining for cytokeratin-18 
(epithelial marker [102, 103]) and vimentin (mesenchymal marker [104]) (see Figure 9).  T80 
cells were utilized as a positive control for cytokeratin-18 and a negative control for vimentin 
while SKOV3 ovarian cancer cell line was utilized as a positive control for vimentin and 
cytokeratin-18 (see Figure 9) [104, 105].  The results indicate that the endometriotic SV40 large 
T antigen expressing cells had strong expression of cytokeratin-18 with undetectable expression 
of vimentin (see Figure 9).    
Presently, we have been able to maintain the SV40 large T antigen expressing 
endometriotic cell lines in culture up to 15 passages. We are still unsure of the effects of long 
term effects of passaging these cells and are continuing to investigate the behavior of the cell 
line.  Interestingly, we have noted that the cells, after a number of passages, begin to proliferate 
at a slower rate suggesting that the cells requires the presence of another immortalization marker 
to become fully immortalized.  We attempted to stably express hTERT in the SV40 large T 
antigen IE cells, but encountered the same high level of toxicity as before.  One potential 
explanation for cell death may be due to hTERTs ability to induce apoptosis in normal human 
cell lines [106].   Furthermore, transformation via Ras or PI3K modulation may be necessary 
before the IE cells can tolerate the addition of hTERT. 
To confirm that the life-span extended endometriotic cells (IE cells) were not altered by 
stable expression of SV40 large T antigen, we compared expression of various protein markers 
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to those expressed in the primary cell lines (endometriotic cells not expressing SV40 Large T 
antigen) (see Figure 9).   Similarly, we detected  low levels of tumor promoting signals (EVI1, 
SnoN), expression of tumor suppressor Smad2/3, and expression of autophagy markers 
(ATG7/ATG5/beclin-1/hVps34) which were all unchanged relative to the primary cells (see 
Figure 9).  This pattern of expression was also compared to the ovarian cancer cell lines, the 
clear cell ovarian cancer TOV21G and endometrioid ovarian cancer TOV112D.  The 
morphology of the life-span extended endometriotic cells was indistinguishable from the 
epithelial endometriotic primary cells.  The only striking difference noted, was the increased 
expression of p53 which could  potentially be explained due to the role of large T antigen in 
inactivating p53 leading to the inability of p53 to turnover (degradation and ubiquitination via 
MDM2 would be expected to be altered) in normal cellular functions (see Figure 9) [100].  
 
Ras and PIK3CA genomic mutations are lacking in IE cells with a “unique” STR profile 
 Since Ras and PIK3CA are considered important mediators in the transition from 
endometriosis to clear cell ovarian cancer, we next assessed the mutational status of the genes in 
the IE cells.  Genomic DNA from IE cells was isolated and primers for PIK3CA (specifically at 
exons 9 and 20) as well as K-Ras (specific for the GTP binding site) were synthesized and 
utilized for sequencing. Their sequences were compared to the normal sequence expression 
derived from T80 parental cells to confirm no mutations were present (data not shown).  
 In order to ensure that the IE cells lack markers of other potentially contaminating cell 
types, we isolated genomic DNA from the IE cells and performed a short tandem repeat (STR) 
profiling analysis (via Genetica Laboratories).  STR is the analysis of repeated segments of DNA 
(roughly 2-6 base pairs) spread through the genome [107]. In brief, Genetica provides a highly 
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sensitive DNA screen of the cell lines provided and compare them available data bases. The 
service is useful for both human and mouse cell types and allows for certainty of cross 
contamination down to 5% of the DNA.  The assessment included a survey of a database of cell 
lines including cells from ATCC. The analysis indicated that the IE cells were unique in origin 
from any other cell type in the databases available to Genetica (data not shown). We are 
presently in process of authenticating the cell line using genomic DNA isolated from the patient.   
 
Inhibition of autophagy hinders IE cell survival 
 Recently, reports have suggested that autophagy is important in the growth and survival 
of endometriotic cells [8, 28, 78, 81, 108].  In brief, one study showed autophagy was critical in 
the basic cyclical functions of the endometrium which express high levels of LC3-II in in vivo 
specimens [78, 108].  In vitro studies also revealed that inhibition of autophagy led to apoptosis 
in normal human endometrial Ishikawa cells [78].  To address whether the immortalized 
endometriotic cells (IE) elicited altered growth survival following inhibition of autophagic flux, 
we tested the effect of the autophagy inhibitor, chloroquine (CQ). This inhibitor prevents 
lysosome fusion with the autophagosome, thus inhibiting autophagic turnover [109].  Successful 
inhibition of autophagy with CQ can be validated via LC3-II accumulation by western analyses.  
Treatment with CQ at 25µM successfully inhibited autophagic turnover as shown via LC3-II 
accumulation (see Figure 10).  Exposure to CQ led to a significant reduction in cell survival 
following 96 hour treatment (see Figure 10). These results suggest that IE cells are “addicted” to 
autophagy which is needed to sustain cell survival. 
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Figure 10: Inhibition of autophagy hinders IE cell growth 
A.  IE cells were treated with 25 µM chloroquine for up to 96 hours.  Cells 
were stained with crystal violet and measured for overall growth.   B. 
Validation of chloroquine inhibition is presented by showing accumulation of 
LC3-II indicative of inhibited autophagic flux.  
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Discussion 
 The field of endometriosis is a rapidly growing research area that has seen significant 
strides in understanding the origins of endometriosis and improving methods of treatment.  
However, the investigative tools needed to carry out endometriosis studies have proven very 
limiting.  In vitro studies have focused heavily on cell lines that are either not validated, proven 
to be misidentified, or questionable in cellular origin [4, 5].   We present herein, our attempts to 
develop a lifespan extended novel endometriotic cell line with epithelial-like characteristics. The 
development of a validated novel cell line will provide a much needed tool for future in vitro 
based studies in the field of endometriosis and clear cell/endometrioid ovarian cancer research. 
IE cells are derived from cells obtained from the normal endometriotic tissue of a patient with 
endometriosis.   These cells contained a mixed population of stromal and epithelial-like cells; the 
latter of which was selected through immortalization with SV40 large T antigen (see Figure 9). 
The data presented in this Chapter demonstrates our successful attempts to isolate 
endometriotic epithelial cells which we confirmed through expression of epithelial marker 
cytokeratin-18 and the absence of vimentin (see Figure 9).  Expression of large T antigen 
expanded the life span of the cells, but did not fully immortalize the cells.  Though we were 
unable to overexpress hTERT in the cells, the IE cells remain an invaluable resource for further 
endometriosis research.  The extension of the IE cell life span allows for further long term 
experiments to be performed.  Although hTERT immortalization failed with the selected IE 
clone, we developed six independent IE cell lines expressing SV40 large T antigen.  Future 
attempts to immortalize IE cells will be performed using the other five clones along with other 
methods for immortalizing the cells (overexpression of Ras or mutation of PTEN).    Further, we 
plan to characterize these cell types to determine if the observations found with IE cells are 
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reproducible.  We have also obtained two other primary endometriotic cell lines (primary A and 
primary B cells) that we are in the process of characterizing and immortalizing.  The 
development of a panel of normal endometriotic cell lines will be invaluable to demonstrate 
reproducibility and extend studies.    
Future studies would focus on markers important in the transition from endometriotic 
cells to a more carcinoma-like phenotype.  Previous work has demonstrated the ability of normal 
cells to acquire cancer-like characteristics with the addition of tumor promoting markers such as 
Ras [105].   We aim to mutate (and overexpress) and silence (knockdown) multiple markers 
including PI3KCA, ARID1A, Ras, and PTEN.  Modulation of the proliferative/survival capacity 
of the cells will demonstrate the significance of these markers in the transformation of such 
gynecological cell types.  
Autophagy also plays an intriguing role in the survival of endometriotic cells.  It has been 
established that the development and shedding of the endometrial lining during the menstrual 
cycle is dependent on autophagic turnover [78].  These reported studies provide convincing 
though limiting insight on the role of autophagy in the endometrial lining.  We sought to develop 
this finding by showing IE cells cease to survive in the presence of the autophagy inhibitor 
chloroquine (see Figure 10).  We have also recently performed a tissue microarray 
immunohistochemical staining of LC3B of tissue specimens derived from various endometriotic 
sites (from the fallopian tube and ovary) and normal eutopic endometrial tissue (data not shown).  
These preliminary studies demonstrated increased LC3 staining in endometriotic lesions in 
comparison to normal proliferative eutopic endometrial tissue suggesting that the development of 
endometriosis may be mediated by increased autophagic flux in the epithelial component.  
Overexpression of autophagic markers such as ULK1 or ATG5 in IE cells may increase the 
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proliferative capacity which could be assessed in vitro as well as in vivo mouse xenograft studies.  
Since treatment with CQ was shown to significantly inhibit cell survival of IE cells, this may 
suggest that IE cells are dependent on autophagy for basic nutrient and metabolic activity [79].  
Indeed, increased autophagic activity may lead to a more robust metabolic response [110, 111]. 
In contrast, since autophagy is also a mechanism of cell death, overexpression of ULK1 or 
ATG5 may induce senescence or cell death [73, 79, 80].  As mentioned in Chapter 1, excess 
production of autophagosomes may be detrimental to vital cell functions thus leading to cell 
death [73, 79, 80].     
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Chapter 4 
 
Iron Modulates Cell Survival in a Ras- and MAPK-Dependent Manner in Ovarian Cells 
 
Introduction 
 Iron is an essential element needed for survival both on a macro (survival of an organism) 
and a micro level (continued growth of a cell) [25, 26].  This element has a unique role in being 
both essential and harmful [13, 112].   Its oxidative/redox nature (ability to gain or lose an 
electron i.e. Fe
+2
 and Fe
+3 
as discussed in chapter 1) allows iron to exist in active (Fe
+2
) and 
inactive states (Fe
+3
) states.  In the Fe
+2 
state, iron can be utilized for a variety of functions 
including metabolism (i.e. citric acid cycle [113]), regulation of DNA synthesis (i.e. DNA 
helicases with iron sulfur complexes [114]), trafficking of oxygen via heme, and translation of 
protein from mRNA [13, 112]. The primary means of obtaining iron occurs through consumption 
of products containing iron or through blood containing iron-rich heme [112].  The presence of 
such a dynamic element can also elicit many negative effects in the cell. The presence of iron can 
lead to increased generation of reactive oxygen species which can lead to cellular damage and 
mutations [13, 70, 112].  These mutations include genomic DNA and mitochondrial DNA 
damage modulating cell regulatory pathways together with increased inflammation [20, 115-
117].  This response can lead to a number of diseases including neurodegeneration, multiple 
sclerosis, and cancer [20, 115, 117].    
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 Endometriosis (a result of menstrual tissue which retrogrades upward) travels through the 
fallopian tube and can implant not only in the peritoneal cavity, but also onto the ovaries [53].  
The lesions can develop into endometriotic cysts.  These cysts are filled with iron rich blood 
particles [13].  They are classified as “chocolate” cysts due to their dark brown coloration arising 
from the presence of “old blood” products.  This iron exposure causes cell stress which can lead 
to DNA damage and mutations thus inducing atypical lesions and increased propensity to cancer 
development [13].  Iron induced ROS has been shown to modulate activator protein 1 (AP-1) and 
NF-kB [20].    Further, cysts are known to spontaneously burst releasing its content into the 
microenvironment leading to increased inflammation [32].  Since heme contributes to the cysts’ 
contents, the microenvironment is also exposed to increased iron levels [13, 51, 118].  
 Interestingly, recent studies have shown a relationship between continual exposure of 
iron and the transformation of ovarian cell types to a carcinoma like state [34].    One study 
demonstrated that exposure of ovarian surface epithelial cells to free iron caused the cells to 
exhibit the behavior of clear cell carcinoma [13, 34].   Another report revealed a correlation 
between higher levels of iron present in the fallopian tubes with an increased rate of serous 
carcinoma [31].  While this suggests that iron plays an important role in cellular transformation, 
the underlying mechanism of this process or positive effect on survival remains elusive in 
ovarian cancer. 
 We propose that the exposure of iron to “normal” (immortalized cells) gynecological cell 
types will lead to transformation to a more carcinoma like nature.   To obtain a broad 
understanding of the effects of iron in gynecological cell types, we obtained a diverse group of 
cell lines to represent the heterogeneous nature of ovarian carcinoma.  As discussed in Chapter 1, 
autophagy can act as both a cell death mechanism and a cell survival pathway.  Due to the ability 
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of iron to induce ROS, we hypothesized that this may lead to activation of autophagy [29, 79].  
Autophagy can serve to remove damaged proteins or organelles allowing for continued cell 
survival [79].  Interestingly, autophagy may indirectly result in tumor promotion [79].  In order 
to fully understand the role of autophagy, we performed a panel of assays to assess functional 
response (cell death, growth, and metabolic changes) to iron.  To determine autophagic 
induction, we identified the formation of autophagosomes as well as its importance in iron 
response (inhibition of autophagy).  We aimed to assess not only how the cell growth is 
modulated, but if excess iron could modulate cell death pathways.   
 Treatments were carried out with ferric ammonium citrate (FAC).  FAC was selected for 
the treatments due to its ease of solubility in aqueous solutions.  Previous reported studies have 
shown success utilizing FAC as well [63].  We also attempted iron sulfate but the compound 
rapidly precipitated upon addition to cell culture media [119]. Not only would this lead to 
cellular stress but also lead to reduction in total iron intake (lower effective iron dose).  A 250 
µM dose of FAC was selected based on previous studies [13, 63].  Importantly, 250 µM is the 
level of iron often found in endometriotic cysts [85]. Herein, we show that iron modulates the 
autophagy pathway of gynecological cell types.   Growth and cell death assays revealed that 
serous (HEY) and clear cell (TOV21G) carcinoma cell lines are significantly more sensitive to 
iron treatment relative to non-cancer cell types and endometrioid carcinoma (TOV112D) cell 
types.   HEY and TOV21G contain mutations in Ras which suggests that the Ras pathway may 
induce iron sensitivity [120, 121].  Use of ovarian surface epithelial cells, T80, with 
overexpression of Ras confirmed this hypothesis.   Interestingly, all of the cell lines expressed 
similar levels of altered metabolism, cell cycle progression, and wound healing responses 
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suggesting that iron elicits a global role in modulating the functional properties of gynecological 
cell types.  
 
Results  
Iron inhibits cell growth in Ras overexpressing/mutated cell lines 
To investigate changes in cell growth, we performed a crystal violet cell growth assay.  
The results show differential response to treatment with iron.  The normal cell types T80 and IE 
cells showed no significant change in proliferation (see Figure 11).  We also investigated the 
human endometrial cell line, HES. While it showed similar trends with T80 and IE cells, it was 
recently reported that HES cells express markers of HeLa cells [4].  Our initial studies were 
performed before this study was released and we opted to halt further use of HES cells for our 
investigations.  Further, the endometrioid carcinoma cell type (TOV112D) showed only slight 
decrease in growth as well (see Figure 11).  In contrast, serous (HEY) and clear cell carcinoma 
(TOV21G) cell types showed significant decreases in overall cell growth suggesting these cells 
are sensitive to excess iron (see Figure 11).  Interestingly, both HEY and TOV21G cells contain 
Ras mutations leading to constitutively active expression.  Ras mutations are a common 
occurrence in ovarian cancer occurring in about 30% of the patient population [18, 61, 105, 122].  
To determine if this mutation contributed to reduced cell survival, we obtained T80 cell lines that 
contained either H-Ras or K-Ras overexpression (see Figure 11) [105].  These cells were treated 
under the same conditions; strikingly, the cell types showed decreased cell growth upon 
treatment with FAC.  To further understand why cell growth decreased with iron treatment, we 
performed an apoptosis assay to delineate the mechanism underlying cell growth decreased with 
iron treatment (see Figure 11).  Twenty percent of the HEY cell population were in early 
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apoptosis and another 20% were in late apoptosis (necrosis) (see Figure 11).   Since a large 
percentage of HEY cells were in late apoptosis and had a distinct necrotic appearance, we next 
performed an LDH assay to determine the percentage of necrotic cells following iron treatment.  
The LDH assay showed a dramatic increase in cytotoxicity supporting earlier evidence that FAC 
induces necrosis in HEY cells (see Figure 11). Interestingly, the TOV21G clear cell line showed 
no significant changes in PI or Annexin V staining.  This suggests the mechanism of cell death 
may vary between cell lines and another mechanism of cell death/reduced cellular viability may 
be occurring in TOV21G cells following treatment with iron. 
 
Iron modulates multiple cellular functions in gynecological cell types 
Treatment with iron after 18 hours leads to distinct morphological change in the 
gynecological cell types tested.  The morphology of multiple cell types could be described as  
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Figure 11: Iron inhibits cell growth in Ras overexpressing/mutated cell 
lines. 
Continued on following page 
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Figure 11: Iron inhibits cell growth in Ras overexpressing/mutated cell 
lines.  
Continued on following page 
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spindle-like together with a decrease in cell size.  We carried out an ATP viability assay to 
determine metabolic changes due to excess iron.   ATP levels decreased in combination of FAC 
suggesting that iron-induced cellular arrest occurred as a result of diminished ATP levels.  HEY 
and TOV21G cells showed greatest reduction of ATP levels after iron treatment (see Figure 11).  
This is likely due to the overall decreased number of cells and decreased growth observed.    
 Since FAC decreased metabolic activity, we were interested if this would result in other 
changes in cellular development. We performed a wound healing assay to see if iron would 
Figure 11: Iron inhibits cell growth in Ras overexpressing/mutated cell 
lines. 
A. Crystal violet growth assays were carried out over a 96 hours period of time 
on T80, T80 + H-Ras, T80 + K-Ras, IE, HES, TOV112D, HEY, and TOV21G 
cell lines.  Cells were treated with 250 µM FAC.  B.  The percent change in 
growth was documented for each cell type relative to its untreated control.  C.  
T80, T80 + H-Ras, HEY, and TOV21G cells were treated with 250 µM FAC 
for 72 hours.  Adherent and floating cells were collected and treated with 
Annexin V and Propidium Iodide (PI).  They were then assessed via flow 
cytometry.  Light microscopy images show images before collection and the 
graph represents changes in alive, early, and late apoptotic cells.   D.  LDH 
cytotoxicity assay was performed on HEY cells treated with FAC for 72 hours. 
E. All cells lines assessed via growth assay were also screened for ATP levels 
after 72 hours of FAC treatment.   
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reduce the ability of gynecological cells to migrate.  Treatment with FAC reduced the ability of 
gynecological cells to fill-in the wounded area in comparison to untreated cells (see Figure 12).  
Untreated cells covered the wound after 30 hours of treatment while the iron treated cell types 
showed marked inhibition.  Further, iron showed a slight but significant change in the cell cycle 
progression (see Figure 12).  Iron halted gynecological cell progression (T80, HEY, TOV21G, 
TOV112D) in G1 by 5% and reduced the cell number present in S phase by 3% (data not 
shown).   These percentages varied with each cell type with a small but significant increase of 
cells in G1 phase.  
 
Iron treatment induces autophagy  
 We observed distinct formation of vacuoles upon treatment of iron with all gynecological 
cell types.    Vacuoles are considered potential markers for autophagic activation which provided 
motivation to investigate further additional markers of autophagic activation [123]. These 
vacuoles were first detected in robust levels in T80 cells and we initially carried out our 
investigation with these cells as a model (see Figure 13).  Vacuole formation, however, could be 
indicative of multiple cell phenomena including accumulation of lipids and aggregates.  Thus, 
validation with tested markers of autophagy is required before confirmation of autophagy 
activation [123].  Treatment with FAC up to 30 hours shows increase in LC3-II which is 
suggestive of the formation of autophagosomes (see Figure 13).  To confirm autophagosome 
formation with other gynecological cell types, we performed another western blot analysis of 
LC3-II looking at 18 hours of treatment (see Figure 13).  The panel of cell lines all show increase 
in LC3-II suggesting autophagy was induced in all gynecological cell types tested (see Figure 
13).   We also investigated changes in p62 but observed variable response.  Although p62 is 
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traditionally thought to decrease during autophagic activation, there are additional functions 
reported for p62 which thus explains this variability  
                                      
            
 
 
 
 
Figure 12: Iron modulates cellular functions in gynecological cell lines. 
A. Cell cycle analysis was performed on T80 cells treated with FAC for 30 
hours.   Slight but significant increase in G1 and decrease in S phase were 
reported.  Similar trends were seen in HEY, TOV21G, and TOV112D cells 
(data not shown).  B. Wounds were developed in confluent plate followed by 
treatment with and without FAC for 18 hours.  Cells were imaged via light 
microscopy.   
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 (data not shown) [124, 125]. Since autophagic response was similar across multiple cell lines, 
we decided to utilize the T80 cells to elucidate the mechanism for autophagy induction. 
An N-terminal EGFP-LC3 plasmid was transfected into T80 cells followed by 18 hour 
treatment of FAC (see Figure 13).   Cells were viewed via direct immunofluorescence viewing 
for the presence of LC3 punctae (see Figure 13).  If autophagy is occurring in the cell, the EGFP-
LC3 would change from a diffuse green, to punctate formation suggestive of conversion from 
LC3-I to the lipidated LC3-II form (see Figure 13).  Two hundred cells per experimental 
replicate were analyzed for distribution of LC3-II, specifically diffuse versus punctate 
localization.  We set a minimum of 20 punctae per cell as a requirement to confirm the presence 
of autophagosomes [98, 123].  Treatment with FAC showed more than a 3-fold increase in cells 
undergoing autophagic flux, supporting the LC3 results obtained via western analysis.   
 Since increase of LC3-II is only an indication of increased autophagosomes and not 
increased autophagic flux which involves turnover (fusion of autophagosome with the 
lysosome), further studies were required. To address this question, we utilized the autophagy 
inhibitor chloroquine (CQ) to determine if FAC increased autophagic flux.  CQ inhibits the 
fusion of lysosomes with autophagosomes leading to an increased accumulation of LC3-II 
(interpreted through western analysis) (see Figure 13).  If the level of LC3-II is higher in 
combination of chloroquine with FAC in comparison to chloroquine alone, this indicates that 
autophagic turnover is occurring via FAC treatment.  In all cell lines, we found that 250µM FAC 
leads to increased LC3-II in combination with CQ in comparison to cells treated with CQ alone 
(see Figure 13).   Interestingly, iron treatment at 5mM levels prevented autophagic turnover 
suggesting that extremely high levels of iron can block autophagic flux.   Along with CQ, we 
utilized a free GFP-LC3 assay to examine autophagic activity [126].   In this assay, the plasmid 
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has a C-terminal tagged GFP to LC3.  The C-terminus is cleaved upon conversion of LC3-I to 
LC3-II which liberates the GFP portion into the cytosol.  Increase of untagged GFP would be an 
indication of increased autophagic flux.   We performed this study with HEY cells and found 
increase of GFP in tandem with increased LC3-II with FAC treatment (see Figure 13).   Further, 
the increased presence of autophagosomes was visualized via transmission electron microscopy 
(see Figure 13).  T80 cells, treated with FAC after 18 hours, were identified to contain distinct 
double bound membrane structures indicative of the presence of autophagosomes (see Figure 13) 
[123].    
We were also interested in understanding the mechanism of autophagic activation via 
iron treatment.  We carried out siRNA transfections for ATG5, ATG7, hVps34, and beclin-1, all 
of which are classic regulators of autophagy (see Chapter 1, Figure 3). Knockdown of ATG5 and 
ATG7 successfully reversed the LC3-II induced by treatment with FAC (see Figure 14).  
However, knockdown of beclin-1 and hVps34 did not inhibit induction of LC3-II; thus leading to 
the inference that FAC-induced activation of autophagy is beclin-1/hVps34 independent (see 
Figure 14).  We validated this by treating with the autophagy inhibitor 3-MA (3-methyladenine) 
which inhibits the PI3K/hVps34/beclin-1 autophagic pathway (see Figure 14).  No changes were 
observed in LC3-II levels with the addition of this inhibitor suggesting that beclin-1/hVps34 
does not play a role in iron-induced autophagy.  We were also interested to see if autophagy 
activation was beneficial to iron treated cells.  Thus, we investigated the changes in cellular 
response to iron upon knockdown of ATG5 and ATG7.  We carried out growth and ATP 
viability assays to determine if any change would occur in HEY cells (see Figure 14).   There 
was only a slight but significant change suggesting autophagy plays at most a minimal role in  
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Figure 13: Iron treatment induces autophagy. 
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Figure 13: Iron treatment induces autophagy. 
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Figure 13: Iron treatment induces autophagy. 
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iron induced cell death.   We also performed these studies with T80 cells and found no 
significant modulation in T80 cell growth with and without iron treatment in the presence of 
ATG5/7 siRNA (data not shown). 
 
Treatment with iron leads to increased lysosomes in a Ras-independent manner 
 Along with an increased presence of autophagosomes, the TEM studies revealed an 
increased number of lysosomes after 24 hours of treatment in T80 cells (see Figure 15).  The 
large lysosome structures (around 1.2 m ranging on the high end of lysosome size) could 
potentially be late stage autophagolysosomes [123].  These structures are the end product of 
autophagy, where the inner membrane is broken down and the contents are degraded.  
Figure 13: Iron treatment induces autophagy. 
 A. Light microscopy (40x) image of T80 cells treated with 250 µM FAC for 
30 hours.  B. T80 cells treated with iron for 18 hours were analyzed via TEMs.  
Arrows indicate double bounded membrane autophagosomes.  C.  Lysate of 
iron treated T80 cells was assessed for LC3-II levels at increasing doses of 
FAC (5 µM to 10 mM).  D. T80 cells treated with 250 µM FAC over multiple 
time points (0 h to 30 h).  E. 18 hour 250 µM FAC profile of T80, HEY, 
TOV112D, and TOV21G cell lines.  F. IE cells treated with increasing doses 
of FAC (250 µM to 5 mM) over 18 hours.  G.  T80, HEY, TOV21G, and 
TOV112D cells treated with 250 µM FAC, 5 mM FAC, 25 µM CQ, or a 
combination of FAC and CQ were assessed after 18 hours of treatment.   H. IE 
cells were treated with 250 µM FAC, 5 mM FAC, 25 µM CQ, or a 
combination of FAC and CQ and lysate was collected and analyzed.  I. HES 
cells were treated with 100 µM FAC, 250 µM FAC, 5 mM FAC, 25 µM CQ, 
or a combination of FAC and CQ. J. HEY cells were transfected with GFP-
LC3 and then treated with 250 µM FAC and then assessed.  K.  T80 cells were 
transfected with EGFP-LC3 and then treated with FAC at 250 µM.  An 
inverted fluorescence microscope was used to assess samples.  Cells with 
greater than 20 punctae were classified as autophagy positive cells. 
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Interestingly, we also observed the presence of iron particles inside of the lysosomes.  This was 
validated using iron dissolved in liquid media (see Figure 15).  The iron particles were 
determined to be 2-3nm in size.  These particles were detected in clusters inside the lysosomes 
following 24 hours FAC treatment (see Figure 15).  To validate the changes in lysosomes 
observed by TEM, we carried out a lysotracker analysis of T80 as well as other cell lines 
investigated in this study.    
Lysotracker is highly selective for acidic organelles, specifically lysosomes..  We also 
were interested in confirming the presence of iron inside the lysosomes.  To achieve this, we 
stained with Calcein-AM which is a cell permeable chemical that is classically used to assess cell 
viability (see Figure 15) [127].  Calcein-AM, however, fluoresces in the presence of iron and 
thus is a useful tool for detection of localization of the element as well [128].   We treated T80 
cells for 24 hours and stained with Lysotracker Red and Calcein-AM and found an increase of 
both lysosomes and iron in the cells (see Figure 15).  We also found co-localization of the two 
stains supporting the TEM findings of iron being present within the lysosome (see Figure 15).  
Interestingly, HEY cells showed no increase of lysosome number after 24 hours of FAC 
treatment together with a diffuse Calcein-AM staining (see Figure 15).  This suggests HEY cells 
may undergo lysosomal permeabilization when exposed to iron leading potentially to cell death.  
However, this observation was not seen in T80 + H-Ras cells where there was no significant 
difference in lysosome numbers compared to T80 parental cells (see Figure 15).  This suggests 
iron-induction of lysosomes occurs independently of Ras modulation.  We quantified the 
Lysotracker Red 
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Figure 14: Iron induced autophagy is ATG5/7 dependent and beclin-
1/hVps34 independent 
Continued on following page. 
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Figure 14: Iron induced autophagy is ATG5/7 dependent and beclin-
1/hVps34 independent 
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Figure 14: Iron induced autophagy is ATG5/7 dependent and beclin-
1/hVps34 independent 
A. T80 cells were transfected with ATG7 and beclin-1 siRNA followed by 
treatment with 250 µM FAC.  Cell lysate was assed for proteins as indicated.  
B. T80 cells were transfected with ATG5 and hVps34 siRNA followed by 
treatment with 250 µM FAC.  Cell lysate was assed for proteins as indicated.  
C.  T80 cells were treated with either 250 µM FAC, 5 mM FAC, 2 mM 3-MA, 
250 µM  and 2 mM 3-MA, or  5 mM FAC and 2 mM 3-MA or left untreated.  
D. HEY cells were transfected with ATG5 and 7 siRNA followed by treatment 
with 250 µM FAC and then assessed for protein expression via western 
analysis.  E. HEY cells transfected with ATG5 or ATG7 siRNA were treated 
with 250 µM FAC for 72 hours then assessed via ATP viability and growth 
(crystal violet staining).   
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Figure 15: Treatment with iron leads to increased lysosomes in a Ras 
independent manner. 
Continued on following page. 
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Figure 15: Treatment with iron leads to increased lysosomes in a Ras 
independent manner. 
Continued on following page. 
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Figure 15: Treatment with iron leads to increased lysosomes in a Ras 
independent manner 
A. T80 cells treated with 250 µM FAC for 24 hours were analyzed via TEM at 
x3530 and x8730 magnification.   Lysosomes are indicated by blue arrows B. 
TEM images of T80 cells were assessed for presence of iron inside the 
lysosomes indicated by yellow arrows.  C. T80, T80 + H-Ras, and HEY cells 
were treated with Calcein-AM followed by treatment of 250 µM FAC.  After 
24 hours of treatment, media was removed and replaced with media treated 
with Lysotracker Red.  Cells were images via inverted fluorescents 
microscopy.  D. T80, T80 + H-Ras, and HEY cells were treated with 
Lysotracker Green following treatment with 250 µM FAC after 24 hours.  
Cells were collected and analyzed via flow cytometry.  E.  T80 cells were 
transfected with HSP70 siRNA then treated with 250 µM FAC for 24 hours.  
Cells were treated with Lysotracker Green and analyzed via flow cytomertry 
or assessed via western analysis.  F. Liquid media treated with FAC analyzed 
under TEM at x8730 magnification.  Iron particles were determined to be 
about 3 nanometers in size. 
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findings by flow cytometry with Lysotracker Green and found a similar significant increase of 
lysosomes after 24 hours of iron treatment in T80, T80 + H-Ras, and a lack of lysosomes in HEY 
cells.   
 We were interested to see if lysosome stability contributed to iron-induced cell death of 
HEY cells.  Since HSP70 has been shown to stabilize lysosomes and prevent permeabilization 
[129], we knocked down HSP70 expression using siRNA in T80 cells (see Figure 15).  Loss of 
HSP70 did not lead to a marked modulation in cell survival in the presence of iron (see Figure 
15).  This suggests HSP70 does not influence lysosomal response to iron treatment.   
 
FAC activates the MAPK pathway to modulate autophagy, lysosome numbers, and cell death 
response. 
 The treatment of ovarian cell lines with iron leads to activation of p-AKT and p-ERK, 
starting as early as 30 minutes (see Figure 16).  Expression of these phosphorylated proteins 
were slightly increased and occurred earlier in the Ras modulated cell types in comparison to the 
T80 parental type.  To determine if activation of p-AKT and p-ERK led to increased LC3-II and 
autophagy activation, we utilized inhibitors of each pathway (U0126 for MAPK and LY294002 
for PI3K) (see Figure 16).   Both inhibitors led to a significant decrease in LC3-II levels via 
western analysis and via EGFP-LC3 immunofluorescence studies (see Figure 16).   Similar 
modulation of LC3-II activity was also observed in HEY cells with the U0126 inhibitor (see 
Figure 16). 
 Since HEY cells showed a lack of lysosomes in the presence of iron (24 hour treatment), 
we were interested if the MAPK inhibitor U0126 would modulate lysosome numbers (see Figure 
16).  Strikingly, treatments with U0126 in combination with FAC led to increased lysosome 
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numbers seen via confocal microscopy and flow cytometric analysis (see Figure 16).   Further, 
Calcein-AM tagged iron to be co-localized within the lysosomes present in the U0126/FAC 
treated samples.  This suggests the presence of lysosomes is critical for survival of iron treated 
HEY cells.    
 We next tested if the PI3K and MAPK inhibitors would result in reversal of cell death in 
Ras mutated and overexpressed cell types.   The PI3K inhibitor, LY49002, did not reverse cell 
death in Ras mutated cell types suggesting that activation of this pathway did not correlate with 
survival (see Figure 16).  However, the MAPK inhibitor, U0126, showed significant and near 
complete reversal of cell death in all Ras mutated and overexpressing cell types.  Further, the 
necrosis response observed with HEY cells upon FAC treatment could also reversed with U0126, 
as determined via an LDH assay (see Figure 16).   
 
Ras expression leads to HO-1 induction in response to iron treatment.   
 HO-1 serves as a rate limiting enzyme in the breakdown of heme into iron, biliverdin, 
and carbon monoxide [9, 10]. We investigated whether this regulator of iron was modulated 
during iron treatment. We treated T80 and T80 + H-Ras cells with iron at 48 and 72 hours and 
found increased protein expression of HO-1 protein and mRNA (see Figure 17).  Interestingly, 
the overall level of HO-1 was higher in the Ras overexpressing T80 cells via protein expression.   
This was confirmed via mRNA levels showing significantly higher HO-1 levels in H-Ras cells.   
To determine the mechanism of HO-1 induction, we knocked down NRF2 which serves as a 
regulator of antioxidant activity and HO-1 transcription [10].  We used siRNA to reduce 
expression of NRF-2 in T80 cells and treated with FAC (see Figure 17).   We found no 
modulation in HO-1 mRNA expression suggesting that HO-1 induction is NRF-2 independent.    
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Figure 16: FAC activates the MAPK pathway to modulate autophagy, 
lysosome numbers, and cell death response. 
Continued on following page. 
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Figure 16: FAC activates the MAPK pathway to modulate autophagy, 
lysosome numbers, and cell death response. 
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Figure 16: FAC activates the MAPK pathway to modulate autophagy, 
lysosome numbers, and cell death response. 
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Figure 16: FAC activates the MAPK pathway to modulate autophagy, 
lysosome numbers, and cell death response. 
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Figure 16: FAC activates the MAPK pathway to modulate autophagy, 
lysosome numbers, and cell death response. 
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Figure 16: FAC activates the MAPK pathway to modulate autophagy, 
lysosome numbers, and cell death response. 
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Figure 16: FAC activates the MAPK pathway to modulate autophagy, 
lysosome numbers, and cell death response. 
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Figure 16: FAC activates the MAPK pathway to modulate autophagy, 
lysosome numbers, and cell death response. 
A. T80, T80 + H-Ras, and T80 + K-Ras cells were treated with 250 µM FAC 
between 1 h to 18 hours.  Lysate was collected and analyzed via western 
analysis. B. T80, T80 + H-Ras, and T80 + K-Ras cell lysate was collected and 
assessed via western.  C. T80 and T80 + H-Ras cells were treated with 250 
µM FAC between 5 mins and 3 hours and assessed via western.  D. T80 cells 
were treated with 10 µM U0126, 250 µM FAC, or 10 µM U0126 and  250 µM 
FAC for 18 hours in the first western blot and treated with 25 µM LY294002, 
250 µM FAC , or 25 µM LY294002  and  250 µM FAC for 18 hours in the 
second. E. T80 cells were transfected with EGFP-LC3 followed by treatment 
of 10 µM U0126, 250 µM FAC, 10 µM U0126 and 250 µM FAC, 25 µM 
LY294002, or 25 µM LY294002 and  250 µM FAC for 18 hours.  Cells were 
imaged via inverted fluorescents microscopy.  F. Quantifiable data from E. 
was assembled.  Cells with greater than 20 punctae were classified as 
autophagy positive cells.  G. HEY cells were treated with 250 µM FAC 
between 1 hour and 18 hours.  Lysate was collected and assessed via western.  
The second study treated HEY cells with either 10 µM U0126, 250 µM FAC, 
or 10 µM U0126 and 250 µM FAC for 18 hours.  H.  HEY cells were treated 
with Calcein-AM followed by treatment of 10 µM U0126, 250 µM FAC, or 10 
µM U0126 and 250 µM FAC.  After 24 hours of treatment, media was 
removed and replaced with media treated with Lysotracker Red.  Cells were 
images via inverted fluorescents microscopy.  I. HEY cells were treated with 
Lysotracker Green following treatment with 10 µM U0126, 250 µM FAC, or 
10 µM U0126 and 250 µM FAC after 24 hours.  Cells were collected and 
analyzed via flow cytometry.  J. T80, T80 + H-Ras, HEY, TOV112D, and 
TOV21G cells were treated with 10 µM U0126, 250 µM FAC, 10 µM U0126 
and 250 µM FAC, or DMSO.  Cells were stained with crystal violet after 96 
hours of treatment.  K. HEY cells were treated with 10 µM U0126, 250 µM 
FAC, 10 µM U0126 and 250 µM FAC, or DMSO for 72 hours and then 
assessed for LDH activity.   
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Figure 17: Elevated Ras expression induces increased HO-1 induction in 
response to iron treatment. 
Continued on following page. 
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Figure 17: Elevated Ras expression induces increased HO-1 induction in 
response to iron treatment. 
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Figure 17: Elevated Ras expression induces HO-1 in response to iron 
treatment 
A. T80 and T80 + H-Ras cells were seeded and immediately treated with 250 
µM FAC for 48 and 72 hours and assessed via western analysis.  B. T80 and 
T80 + H-Ras cells were seeded and immediately treated with 250 µM FAC for 
72 hours.  RNA was extracted from the samples and real time PCR analysis 
was performed on HO-1 expression.  C.  T80 cells were transfected with 
NRF2 siRNA and then re-seeded and immediately treated with 250 µM FAC 
for 72 hours.  RNA was extracted and used to analyze HO-1 and NRF2 levels 
via real time PCR.  T80 cells treated with As2O3 were also assessed for HO-1 
mRNA levels to serve as a positive control.  NRF2 knockdown was confirmed 
via western analysis as well.  D/E. T80 cells with HO-1 retroviral stable 
overexpression were generated and assessed via protein level (western 
analysis) and RNA level via RT-PCR.  F. A growth assay of T80 and T80 HO-
1 cells was performed over 96 hours to assess relative change in growth due to 
HO-1 overexpression.   
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To determine the role of HO-1 in iron treatment, HO-1 retroviral stable T80 cells were created 
(see Figure 17).   Increased expression lead to decreased cell growth suggesting HO-1 serves to 
hinder cell growth.  We attempted to develop stable HO-1 overexpressing T80 + H-Ras cells.  
Unfortunately, the cells already express resistance to puromycin selection marker associated with 
the HO-1 plasmid construct.      
   
       
 
 
 
 
Iron chelator, desferrioxamine (DFO), induces cell death in gynecological cell types 
 Iron chelators are able to interact with iron by removing it from the cell.   The exact 
cellular mechanism for iron chelators is not fully understood, but some studies suggest that 
degradation of ferritin occurs reducing the ability to utilize iron [11].  We utilized 
desferrioxamine (DFO), a chelator that is FDA approved  to treat patients for iron overdose [11].   
DFO removes both intracellular and extracellular iron from the environment (see Figure 18).  We 
initially utilized DFO with treatment with FAC to see if activation of autophagy was reversible 
Figure 18: Model of DFO interaction with intercellular iron.    
DFO is cell membrane permeable allowing for DFO to easily enter the cell.   
DFO actively binds to iron and upon association prevents iron from being 
utilized for cellular functions [11].   *Model created by Kyle Bauckman. 
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upon inhibition of iron.   We found that DFO was able to inhibit the autophagic effects of iron at 
a 1:1 ratio of treatment (250 µM each) (see Figure 19).  We confirmed this via LC3 western 
analysis and EGFP-LC3 immunofluorescence (see Figure 19).  Surprisingly, we found DFO 
treatment alone led to an increase of cell death and shrunken cell morphology.   Since the cells 
were confirmed to not be undergoing autophagy and the membrane integrity was not lost 
(necrosis), we investigated the possibility of apoptosis occurring in DFO treated cells (see Figure 
19).   We detected an increase in cleaved PARP after 18 hours of DFO treatment in T80 cells.  
Interestingly, the addition of iron at a 1:1 ratio led to a decrease of cleaved PARP suggesting the 
presence of increased iron helps bring equilibrium to the cell (see Figure 19).   To test this, we 
performed growth assays on T80, HEY, and TOV21G cells to see if combination of FAC and 
DFO would reverse loss of cell growth.   The combination at 1:1 led to a slight but significant 
increase in cell growth in all cell lines tested.  Since the gynecological cell lines we tested were 
sensitive to DFO at a level considered to be a normal dose, we performed a kill curve growth 
assay (see Figure 19).  We found that all gynecological cell types we tested were sensitive to 
DFO treatment down to 1 µM levels. 
 
Iron does not modulate adhesion 
 To observe effects of iron on cell adhesion, TOV21G cells were seeded into 96 well 
plates and treated with or without iron.  The plates were pre-treated with either laminin, 
fibronectin, or left untreated.  Cells were allowed to attach for one hour and then plates were 
stained with crystal violet.  Treatment with iron did not appear to modulate cell adhesion under 
any of the conditions tested suggesting iron does not lead to altered adhesion abilities (see Figure 
20).   
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Figure 19: Iron chelator, DFO, induces cell death in gynecological cell 
types 
Continued on following page. 
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Figure 19: Iron chelator, DFO, induces cell death in gynecological cell 
types 
Continued on following page. 
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Figure 19: Iron chelator, DFO, induces cell death in gynecological cell 
types 
Continued on following page. 
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Figure 19: Iron chelator, DFO, induces cell death in gynecological cell 
types 
 A. T80 cells were treated with 100 µM DFO, 250 µM DFO, 250 µM FAC, 
100 µM DFO and 250 µM FAC, 250 µM DFO and 250 µM FAC, or left 
untreated for 1 hour and 18 hours.  B/C. T80 cells were transfected with 
EGFP-LC3 followed by treatment of 250 µM DFO, 250 µM FAC, 250 µM 
DFO and 250 µM FAC, or left untreated for 18 hours.  Samples were imaged 
via inverted fluorescence microscopy.  Cells with greater than 20 punctae were 
classified as autophagy positive cells. D. HEY cells were treated with 100 µM 
DFO, 250 µM DFO, 250 µM FAC, 100 µM DFO and 250 µM FAC, 250 µM 
DFO and 250 µM FAC, or left untreated for 1hour and 18 hours.  E. HEY, 
TOV21G, and TOV112D cells were treated with 250 µM DFO, 250 µM FAC, 
250 µM DFO and 250 µM FAC, or left untreated for 96 hours and then stained 
with crystal violet to assess growth.  F. T80, HEY, TOV21G, and TOV112D 
cells were treated with DFO from 100 nM to 25 µM and assessed for growth 
changes.  G. HEY and TOV21G cells were treated with DFO and FAC from 1 
to 25 µM in dose and in combination to assess for growth changes.   
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Long term iron exposure modulates LC3-II expression and morphology of normal ovarian 
surface epithelial cells (T80) 
 Previous investigations have shown that continued exposure to iron leads to altered 
cellular morphology, specifically a clear cell appearance [34].  This would suggest iron has  
                                 
 
 
 
 
 
transformative effects on “normal” gynecological cell types.  We wanted to induce this response 
in T80 cells with continued exposure of FAC to observe the long term autophagic response.   We 
treated T80 cells weekly with 250 µM iron changing the media and adding fresh iron each time.  
Cells were passaged once confluent and then continued to be treated with FAC once re-seeded.  
After one month of exposure to FAC, T80 cells went through an initial period of cell death 
followed by the formation of small colonies.  The growth of these colonies slowed dramatically 
but remained viable.  After a week of observing this phenomenon we decided to remove the 
Figure 20: Iron does not modulate adhesion  
A. TOV21G cells were seeded on 96 wells plates treated with fibronectin, 
lamin, or nothing and allowed to adhere for 1 hour.   Cells were treated with or 
without FAC.  After 1 hour media was removed and cells were stained with 
crystal violet.  Treatment with FAC did not increase the ability of cells to 
adhere to wells. 
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colonies and grow them in individual plates without iron.  Interestingly, once the iron was 
removed, the colonies resumed cell growth.  Continued treatment of iron followed similar 
response with initial loss of cells, followed by the continued presence of small colonies.  We 
harvested these cells and compared them to normal T80 cells untreated and treated with iron and 
observed altered LC3-II levels (see Figure 21).  However, the change in LC3-II expression was 
quite variable with some samples showing distinct changes in LC3-II relative to the parental T80 
population and others showing no distinct changes (see Figure 21).  These observations led to 
difficulty in drawing a definitive conclusion.  Further investigations should utilize parental T80 
cells treated with and without FAC to compare change in LC3-II expression.   
Treatment with FAC in HEY cells led to a rapid and robust level of cell death.  While iron 
reduced HEY cell numbers significantly in all survival assays performed, there were always a 
few cells remaining.  These cells though altered in morphology (compared to controls), were 
surviving.  We were interested in the ability of these remaining cells to continue growing and 
developing.   A single 35mm dish of HEY cells was treated with 250 µM iron for long term 
observation.   To ensure cell growth was due to resistance to iron induced cell death and not iron 
depletion, we changed the media with fresh iron treated media daily.   After continual exposure 
with iron, colonies grew and developed into a resistant iron cell type (data not shown).   This 
suggests that iron may have a dual role in ovarian cells.   Though iron leads to robust cell death 
in Ras mutated/overexpressing cell types, this may be a means of rapidly selecting more robust 
and potentially more aggressive cells.  Further studies are required to fully investigate the 
cellular mechanisms underlying FAC mediated resistance.  Future studies will utilize these cells 
in comparison to parental HEY cells to observe functional and cell signaling pathway alterations.   
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Discussion 
 The initial assessment of the functional response of iron was carried out via a cell growth 
assay.  We were interested in observing the potential benefits or modulation of cell types upon 
exposure to iron.  Surprisingly, we observed minimal changes in all of the selected cell types 
with the exception of HEY and TOV21G cells (see Figure 11).   Interestingly, these cells both 
have a K-Ras mutation, a pathway that a recent publication has shown to be connected with a 
novel iron induced cell death pathway known as ferroptosis [3].   We were particularly interested 
in this discovery of a novel cell death pathway due to its similarities to our studies.  Both our 
findings and the Dixon [3] group have identified that iron induced cell death mediated by the Ras 
Figure 21: Long term iron exposure modulates LC3-II expression and 
morphology of normal ovarian surface epithelial cells (T80) 
A. T80 cells were treated with continuous treatments of iron (Long term FAC 
or LTF).  Fresh iron was added every other day.  Colonies were selected after 
weeks of continuous treatment.  These colonies were treated further.  Samples 
of colonies were taken for western analysis that were treated continuously with 
FAC or had iron removed for 48 hours.    
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pathway leads to loss of plasma membrane integrity.  Further, the ferroptosis paper [3] reports 
altered mitochondrial morphology which we address in Chapter 6.   Interestingly, another group 
also reported ferroptosis with the added observation of autophagy.  Similar to our studies, 
autophagy did not contribute significantly to cell death.  Though trends are evident between 
Dixon’s work and the data presented here, we do not believe it is appropriate to classify our 
observations as ferroptosis.  The mechanism has not fully been established and the characteristics 
of ferroptosis are still not well-defined.   Our primary concern is that ferroptosis closely 
resembles necrosis.  This is a point that is addressed by Dixon and colleagues but remains 
unclear [3].  We propose that ferroptosis may simply be a form of necroptosis. 
We continued our investigation into the Ras-dependent cell death effects of iron in the 
following chapter (6).  Confirmation of cell death was determined via an apoptosis assay that 
revealed increased apoptosis and necrosis in HEY cells (see Figure 11).   Interestingly, no 
change in early or late stage apoptosis was detected in TOV21G cells.  This implies other means 
of cell death for TOV21G.   We performed a β-galactosidase senescence assay but the results 
appeared negative (data not shown).   
Since we observed formation of vacuoles with iron treatment, we hypothesized 
autophagy may play a role in iron induced cell death.  Treatment with iron induced autophagic 
activation in the entire gynecological cell selection tested.   Iron exposure led to a gradual 
increase in LC3-II up to 18 hours along with increased lysosome numbers detected at 24 hours 
(see Figure 13 and 15).  The presence of iron inside of lysosomes at 24 hours suggests that this 
process is important for processing iron.  Indeed, previous studies have shown lysosomes to be 
important in transporting free iron into the cytosol for utilization and further storage [21, 130].  
The lack of lysosomes present in HEY cells infers that lysosomes are critical for ovarian cell 
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types to survive exposure to extracellular iron  Further, the inhibition of autophagy via ATG5/7 
knockdown led to significant reversal, though modest, of decreased cell growth presented in 
HEY cells (see Figure 14).  Since this change was only slight, it may imply that autophagy plays 
only a minor role in the death of HEY cells.   However, since 24 hour exposure of iron showed 
the absences of lysosomes, it is possible that iron leads to lysosomal permeabilization and thus, 
dysfunctional autophagy after long term FAC exposure (post 24 hours).   
 Exposure to iron induced physical change in the treated cells resulting in spindle-like cell 
formation.   Metabolic activity, detected via ATP, was reduced in all cell types due to exposure 
to iron (see Figure 11).  The HEY and TOV21G cell types showed the greatest change in ATP 
levels, but this decrease might reflect the decrease in cell growth (hence decreased cell number) 
and not metabolism alone.   Similar changes in cell cycle and migration imply the exposure of 
excess iron leads to halt in normal cell functions (see Figure 12).  Since continued exposure to 
iron does not lead to significant changes in growth or cell death in the gynecological cells (with 
the exception of HEY and TOV21G) these changes may be a normal response of excess iron.  
The cells’ decrease in ATP levels and wound healing ability may be a temporary response to 
focus on storage and removal of iron.  Time points beyond 96 hours could be assessed to see if 
the cells return to normal metabolic function.   
 Exposure to iron did not lead to a dramatic change in functional responses in the normal 
T80 cells.  Previous investigations suggested exposure of normal cells to continuous levels of 
increased iron would lead to a more clear cell-like cell type [13].   Treatment with iron in T80 
cells lead to altered cell morphology as well as increased induction of LC3-II (see Figure 21).  
However, once iron was removed, the cells gradually returned to a normal morphology and LC3-
II levels returned to original levels.   This suggests that iron exposure can modulate signaling 
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pathways in normal cells and potentially make them more aggressive, but this can only be 
achieved via continued iron exposure.  The presence of a specific mutation may also be required 
to elicit stable expression of cancer like characteristics.  Further, treatment with iron did not 
increase the cells’ adhesive ability (see Figure 22).  However, our studies focused only on the 
ability of cells to adhere in the presence of iron. We propose that future studies could examine 
the ability of cells pre-treated with iron to adhere.  
Finally, we were interested in why ovarian cancer cells with Ras expression would 
respond so dramatically to iron treatment (see Figure 22).  Iron is a naturally occurring element 
in the body and has been shown to lead to the development of clear cell ovarian carcinoma [13, 
34].   Why an element so essential to growth and development would be so damaging to cancer 
growth is a conundrum.   We hypothesized that large levels of stress induced by iron may serve 
            
 
 
 
 
Figure 22: Model of the cellular responses of iron in gynecological cell 
types. *Model created by Kyle Bauckman. 
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as a means of survival.  Thus, this leads to selection of cells that can grow advantageously in an 
iron-rich environment.  Interestingly, we found that a small population of HEY cells treated with 
iron continually survived after 96 hours.  We continued treatment of these cells with iron and 
found that they eventually recovered and become tolerant to iron exposure. This rapid change in 
cell growth response suggests that high iron levels may lead to a more aggressive ovarian cancer 
type.  Future work should focus on the role of iron in long term progression of ovarian cancer.  
These studies should focus on both the ability of iron to induce cell death as well as its ability to 
increase survival long term.    
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Chapter 5 
 
Iron Alters Autophagic and Anoikis Response in Gynecological Cell Lines Under 
Anchorage-Independent Conditions 
 
Introduction 
 Anoikis is a cell death phenomenon that occurs due to the loss of adhesion to the 
extracellular matrix (ECM) [75-77].  This loss of interaction with the ECM leads to an apoptotic 
form of cell death [73, 75, 77].   Interestingly, a critical step in a cells’ transition to cancer is 
acquired resistance to anoikis [73, 75, 77].  The ability of a cancer cell to detach from the ECM, 
survive, and proliferate is a hallmark of metastasis [75].  The transition from an anoikis sensitive 
to resistant state occurs through a number of mechanisms including increased expression of 
integrins and exposure to reactive oxygen species (ROS) [74].  The effects of ROS have been 
reported to be bifunctional [74, 79, 117]. In one aspect, ROS is capable of generating pro-
survival expression patterns leading to a cell type more tolerable to external stress such as 
chemotherapeutic agents [74].  For example, ROS activates mediators in specific signaling 
pathways including Src tyrosine kinase and EGFR, thus hindering apoptosis [131].  Other studies 
have shown that cellular properties critical for cellular adherence at distance metastatic sites is 
dependent on activation of the Ras/MAPK and PI3K pathways [132, 133].    Mutations acquired 
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via exposure to ROS may lead to inactivation of specific genes that sensitize cells to anoikis 
including loss of Rb and p66-Shc [133, 134].   
 Endometriosis may elicit similar characteristics to invasive tumor cells. In this regard, we 
propose that anoikis-resistant endometrial cells travel from their originating location (uterine 
endometrium) to ectopic sites (peritoneal cavity, surface of the ovary, and other sites) via the 
fallopian tube via the process of retrograde menstruation. These endometrial cells maintain the 
ability to survive and proliferate [37, 38].  The ability of endometrial cells to travel to a distant 
site suggests that these cells have acquired resistance to anoikis.  Further, one study has 
implicated increased expression of tyrosine receptor kinase B (TrkB) in eutopic endometrium 
from endometriosis patients (compared to eutopic endometrium from patients without 
endometriosis) leading to anoikis resistance [135]. Previous studies have suggested that 
autophagy is important in the regulation and survival of endometrial cells [78].  Interestingly, 
autophagy has also been found to contribute to anoikis resistance in cancer cells [73, 79].    
As previously described in Chapter 1, recent evidence indicates that iron may play a role 
in the transition from endometriotic lesions (particularly those described as “chocolate” cysts) to 
clear cell-like ovarian cancer characteristics [13, 136].   This transition is considered to occur 
through continued exposure to ROS generated by iron exposure [13].  We hypothesize that iron 
promotes this transition by allowing survival of cells grown under anchorage-independent 
conditions.  Additionally, we propose that autophagy may be a key regulator in the acquired 
anoikis resistance.  Using a simulated three-dimensional in vitro growth assay, we tested whether 
the anoikis (and autophagic) response was altered following iron treatment. The use of tissue 
culture sterile plates coated with poly-HEMA (a hydrogel polymer) has been previously 
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described [134]. This hydrophobic coating prevents cells from adhering to the plate causing them 
to grow in suspension with spheroid morphology (see Figure 23).     
 
 
 
 
 
 
Result 
Iron and autophagy reduces the apoptotic response in ovarian cell lines grown under 
anchorage-independent conditions 
In order to determine whether iron influences cell survival of ovarian cells grown under 
three-dimensional conditions, we utilized poly-HEMA coated plates and treated our panel of 
cells with 250 µM FAC.  This was followed by western analyses of markers of apoptosis 
(cleaved PARP) and autophagic response (LC3-II) (see Figure 24).  Since we previously 
observed that iron induces autophagy via increased LC3-II expression (Chapter 4, Figure 13), we 
thus documented how cells grown in this three-dimensional environment would elicit changes in 
these cell death/survival responses. Interestingly, we identified increases in cleaved PARP in the 
“normal” ovarian cell type (T80) relative to the untreated adherent cells (see Figure 24).   We 
also looked at HES cells and their response to anoikis conditions (data not shown).  
Figure 23: Model of 3D poly-HEMA plate formation.    
Poly-HEMA is placed on cell plates and left to dry.  Two rounds of poly-
HEMA are placed on the plate to ensure full coverage.  Once the plate is 
ready, cells can be seeded into the wells.  The cells are unable to attach to the 
plate leading to the formation of floating colonies.   *Model created by Kyle 
Bauckman. 
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Figure 24: Iron and autophagy reduce apoptosis in ovarian cell lines 
under anchorage-independent conditions  
Continued on following page. 
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These studies were carried out before we became aware that HES cells were HeLa cell 
contaminated [4].  Thus, we limit our interpretations of “normal” gynecological response to T80 
cells.    In contrast, the ovarian carcinoma cell lines (HEY, TOV21G, and TOV112D) did not 
show noticeable changes in cleaved PARP (see Figure 24).  This was an expected outcome as the 
ability of cancer cells to survive anoikis-like conditions are a key characteristic of tumorigenesis 
[137-139].    
Figure 24: Iron and autophagy reduce apoptosis in ovarian cell lines 
under anchorage-independent conditions  
Plates were pretreated with and without poly-HEMA and left to dry overnight.  
Cells were seeded into wells and treated with 250 µM FAC, 25 µM CQ, both, 
or left untreated.  A. T80, T80 + H-Ras, and T80 + K-Ras cells were assessed 
for changes in LC3-II and cleaved PARP after 72 hours of treatment.  2D 
represents cells that adhered to the plate and 3D represents poly-HEMA coated 
plates.   B. Assessed response of anoikis in ovarian cancer cell lines HEY, 
TOV112D, and TOV21G. C. T80 and T80 + H-Ras cells were seeded in poly-
HEMA treated plates for 72 hours and then treated with ethidium bromide.  
Images were viewed via an immunofluorescence microscope.    
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Next, we investigated whether autophagy could influence the anoikis response of ovarian 
cells lines grown under anchorage-independent conditions.   We treated cells with the autophagy 
inhibitor chloroquine (CQ) to determine whether this could alter the apoptotic response 
following autophagy inhibition (see Figure 24).  Treatment with the autophagy inhibitor is well 
established to prevent turnover of autophagy, thus hindering the ability of FAC to activate the 
pathway.  We hypothesized that activation of autophagy induced by FAC would alter cell 
survival in cell maintained under anchorage-independent conditions.    Interestingly, the 
reduction in autophagic flux decreased cleaved PARP in the T80 cells (see Figure 24).  In 
contrast, inhibition of autophagic flux via CQ in cancer cell lines dramatically increased cleaved 
PARP (see Figure 24). These results suggest that autophagic flux appears to be essential in 
modulating the anoikis response. In cancer cell lines, autophagic flux antagonizes apoptosis 
whereas in normal T80 cells, autophagic flux contributes to apoptosis. Thus, a dual role for 
autophagy is noted where it serves to promote anoikis in normal cell types and to oppose anoikis 
in cancer cell types.  Further studies are needed to determine if the cleaved PARP is indicative of 
increased apoptosis.  An apoptosis assay (involving Annexin V/PI staining) will be utilized to 
validate this cleaved PARP response.  We also will investigate if cell death is decreased with 
reduced cleaved PARP.  Loss of cleaved PARP may lead to altered cell death events (to necrosis 
or autophagy) instead of completely reversing the process [140].   
In addition, we assessed the ability of iron to modulate survival of cells grown under 
these above-described anchorage-independent conditions.  Thus, we treated cells with 250 µM 
FAC.  Since we previously demonstrated that FAC was able to induce autophagy (Chapter 4, 
Figure 13), we treated cells with FAC in absence/presence of CQ in order to determine whether 
the FAC cell death response was dependent on autophagic flux. Our results indicate that iron did 
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not alter cleaved PARP response of the ovarian cancer cell lines we tested.  Only minor changes 
in LC3-II were observed in the TOV21G cells.  In contrast, iron treatment of T80, T80 + H-Ras, 
and T80 + K-Ras cell lines decreased cleaved PARP levels suggesting that iron may play a role 
in modulating normal ovarian cell anoikis response.  To further assess the effect of iron and CQ 
on cell survival in the T80 cell lines, we performed a cell viability assay utilizing ethidium 
bromide.  Cells treated with CQ or FAC elicited increased ethidium bromide staining compared 
to the untreated cells (see Figure 24).  Further, the T80 + H-Ras cell line appeared to have denser 
spheroids when treated with FAC or CQ relative to their untreated counterparts.    
 
Discussion 
 Anoikis is a cell death phenomenon that occurs due to loss of adhesion to the ECM [75, 
77, 135].   The ability to survive this detachment promotes cancer cell invasion and metastasis.   
The ability of cancer cells to lose its ability to adhere to the ECM promotes increased propensity 
to metastasize to distant regions of the body [75].  Interestingly, one of the multifactorial 
elements required for development of ectopic endometriotic lesions is the ability of endometrial 
cells (which normally undergo apoptosis following detachment) to travel in a retrograde motion 
from the uterine cavity through the fallopian tube and onto the ovaries as well as other locations 
in the peritoneal cavity [53, 141, 142].   Although the association between anoikis and 
endometriosis is poorly understood, one study has demonstrated increased tyrosine receptor 
kinase B (TrkB) expression which occurs in the eutopic endometrium of patients diagnosed with 
endometriosis (relative to eutopic endometrium from patients with no endometriosis) which 
could potentially contribute to acquired resistance of  these endometrial cells to apoptosis/anoikis 
[135].   
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 Treatment with iron could promote the transition to a clear cell like ovarian cancer 
phenotype in endometrial/endometriotic cell [34].   We wanted to observe iron response in a 3D 
environment to approximate an in vivo response.  Interestingly, we show that iron leads to 
reduction in apoptosis via modulation in cleaved PARP in normal ovarian cell types (see Figure 
25).  This was supported by the increase of ethidium bromide staining in the T80 and T80 + H-
Ras cell types.  We plan to continue these studies by investigating cell death responses via 
apoptosis assays.  This would help to elucidate other mechanisms of cell death (i.e. necrosis, 
apoptosis, etc).   Further, determination of the mechanism of apoptotic death (i.e. intrinsic or 
extrinsic apoptosis) is also critical.   These results indicate that iron may assist in preventing 
Figure 25:  Model of gynecological cell response to anoikis.   
“Normal” cell types will undergo apoptosis shown via increased cleaved 
PARP.  Cancer cells, however, do not undergo PARP cleavage suggesting that 
they are resistant to anoikis.  Treatment with FAC or chloroquine (CQ) leads 
to reduced cleaved PARP and cell death in “normal” cell types.  In contrast, 
these compounds induce cleaved PARP in cancer cells.   *Model created by 
Kyle Bauckman. 
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anoikis, allowing for continued survival and an opportunity to transform into a more aggressive 
cell type (see Figure 25).   While no change in apoptosis was observed in the cancer cell types, 
suggests that there is increased benefit to the cells.  We previously demonstrated that iron 
induced non-apoptotic cell death in cell types with altered Ras mutation/overexpression.  Further 
studies are necessary to validate that these cells are not undergoing cell death.    
 There was also a marked increase in autophagic protein, LC3-II, in both normal cell types 
as well as ovarian cancer cell lines.   Treatment with CQ (inhibition of autophagic turnover via 
hindering lysosomal fusion with autophagosomes) reduced cleaved PARP levels in normal cells 
while enhancing cleaved PARP in cancer cell types (see Figure 24).  This phenomenon has been 
well documented in various autophagy studies [29, 79, 80, 109, 125].  Often, autophagy will 
switch from inducing cell death to inducing cellular survival [79].   The stress induced by an 
anchorage-independent environment leads to apoptotic cell death.  This stress can be reduced by 
activation of autophagy allowing for continued survival (see Figure 25).   In contrast, the loss of 
autophagy may lead to excess cell stress and apoptotic death in the cancer cell types [143-145].   
The T80 cell types showed a reduction of cleaved PARP in the presence of CQ.  A previous 
report demonstrated not only cross talk between autophagy and apoptosis but potentially 
influence each other [146].   Since the anoikis data demonstrated distinct responses in cell 
survival with iron treatment as well as a dependence on autophagy, future studies should focus 
on in vivo models.  In this regard, we plan to study the survival and proliferative capacity of 
normal cells in a mouse endometriosis model.  This model was developed specifically to assess 
the effect of drugs and other agents on the development of endometriotic cysts [147].  Briefly, 
the uterine horn tissue of an estrogen-treated donor mouse is removed and injected into a 
recipient mouse.  This recipient tissue will develop into endometriotic cysts in the peritoneal 
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cavity, similar to development of human endometriosis [147].  Iron treatments can be performed 
on these mice to determine the ability of iron to modulate cyst number and size.      
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Chapter 6 
 
Mechanisms Underlying Iron-induced Responses Downstream of the  
Ras/MAPK Signaling Pathway 
 
Introduction  
 As described in Chapter 4, we determined that the Ras/MAPK pathway increases 
sensitivity to iron (presented as ferric ammonium citrate, FAC).  This was directly supported by 
the T80 +/- H-Ras studies and MAPK inhibitor trials presented in Chapter 4.   In cell lines with 
Ras mutations or overexpression, exposure to iron markedly decreased cell survival with a 
particularly significant necrotic response noted in the HEY serous epithelial ovarian carcinoma 
cell line (Chapter 4) [28].   However, the identity of the downstream mechanism following 
Ras/MAPK activation to this iron-induced response remained elusive.  In our efforts to identify 
these mechanisms, we engaged three independent means of investigation.   
Our initial approach focused on identifying signaling pathways that were modulated 
downstream of the Ras/MAPK cascade.  The translational control pathway was of particular 
interest: (a) identified to be altered from a high-throughput proteomics approach (RPPA, reverse 
phase protein array) and (b) reported cross-talk activity with the AKT pathway [1, 2, 148].   As 
presented in Chapter 4, we identified AKT to be activated following 1 hour FAC treatment 
together with the MAPK pathway [28].   The AKT and MAPK pathways have shown to 
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simultaneously induce translational activation through mTORC1 regulation (see Figure 26) 
[148].  Activation of this pathway appears to promote cell survival, invasion, migration, and 
proliferation [1, 2, 148]. 
 
            
 
 
 
Activation of the translational control pathway leads to phosphorylation of the S6 and p70S6 
kinases thus leading to recruitment of eukaryotic initiating factors (i.e. eIFs) [1].  The formation  
Figure 26: Model of translational control activation [1, 2].  *Model created 
by Kyle Bauckman. 
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of eIF complexes is particularly limited by eIF4E which is found at low levels relative to other 
eIFs.  eIF4E thus becomes the rate limiting step for translational activation [1].  The eIF complex 
Figure 27: Model of the ferroptosis pathway 
A. The pathway was described in Dixon and colleagues paper [3].   The small 
molecule inhibitor erastin inhibits cysteine channel Xc leading to reduced 
levels of cysteine.  This leads to an increase of ROS inducing ferroptosis.  Iron 
chelators DFO and inhibitor Ferrostatin-1 (Ferr-1) can reverse this response.  It 
is speculated that iron may contribute to ROS production, but its exact 
mechanism is yet unknown.   B. A list of traits classifying ferroptosis is 
provided.  *Data is conflicting on the involvement of autophagy. *Model 
created by Kyle Bauckman. 
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forms a cap on the 5’ untranslated region of a given mRNA [1].  This cap assists in the 
translation of the mRNA to protein.   This cap formation can be inactivated by 4E-BP1.  This 
protein binds to eIF4E preventing it from forming a 5’ cap [149].   Phosphorylation of 4E-BP1 
releases eIF4E allowing translational activation to ensue [149].   While Ras-induced translational 
activation is considered a tumor promoting mechanism, modulation of this pathway can also lead 
to expression of pro-death mediators [148, 150].  As presented herein, since we observed that the 
translational control pathway could be altered by iron exposure, we also assessed the 
contribution of this pathway to the iron-induced cell death response in HEY cells using inhibitors 
(i.e. MNK inhibitor) which are known to regulate this pathway. 
In the second approach, we investigated whether signaling events activated by 
ferroptosis, a recently reported novel iron-regulated cell death pathway, occurred following 
Ras/MAPK activation under our conditions [3].  The similarities in ferroptosis to the cell death 
response we observed were intriguing and merited further investigation (see Figure 27). The 
initial study on ferroptosis was reported during publication of our studies presented in Chapter 4.  
Presently, only two groups have published work relating to this pathway [3, 84].   Ferroptosis is 
mediated by the Ras pathway and can be induced by a small-molecule inhibitor of Ras called 
erastin [3].  Further, a novel inhibitor called Ferrostatin-1 was also developed that appears to be 
capable of reversing the iron-induced cell death response [3].  Ferroptosis closely resembles a 
necrotic form of cell death in which loss of membrane integrity occurs.  However, they conclude 
that ferroptosis is simply a novel form of necrotic response. Since we observed that iron 
treatment in the HEY ovarian cancer cell line exhibited loss of plasma membrane integrity 
(indicative of necrosis), we then sought to determine whether iron induced a ferroptosis response 
in this cell line.    
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Our third approach involved investigating whether the iron pathways regulated by IRP1/2 
(iron regulatory protein 1 or 2) could be altered as a result of Ras mutation or overexpression. As 
described in Chapter 1 and Figure 5,  the IRP1/2 proteins are critical for regulating expression of 
molecules in iron uptake (CD71, transferrin receptor and DMT1, divalent metal transporter), 
preprocessing (ISCs), iron utilization (FTH, ferritin), and export (ferroportin and hepcidin) in the 
cell [25].   Intercellular uptake of iron occurs through the transferring receptor which becomes 
internalized into endosomes [25].   Here, iron is converted from Fe
+3
 to Fe
+2
 via ferroreductases 
such as STEAP proteins and is then exported into the cytosol via DMT-1 [25]. This bioactive 
iron (as Fe
+2
) is redox-active and can bind to IRP1 to regulate its RNA-binding activity [19].  
Under conditions of excess iron, it may be stored by binding to ferritin or exported out of the cell 
by ferroportin [25].  Ferroportin, itself, is regulated by a small peptide hormone called hepcidin.  
Hepcidin is produced and regulated by the liver.  Cell exposure to hepcidin  leads to degradation 
and internalization of ferroportin [25].  Interestingly, high levels of hepcidin have been observed 
in breast cancer patients [69].  Similarly, breast cancer patient tissue and cancer cells express low 
levels of ferroportin promoting iron retention [69].  In addition, iron is needed for production of  
iron-sulfur clusters which regulate proteins critically involved in transcription, translation,  and 
cellular respiration (i.e. aconitase, electron transport chain, citric acid cycle [21]), amongst many 
others [22, 25, 29, 68, 70].  Iron-sulfur clusters are generated in the mitochondria and thus iron 
needs to be imported into this organelle via as yet unknown transporters [21, 22, 63, 64, 68, 113, 
116].  Intriguingly, frataxin (FTX), a mediator of mitochondrial iron-sulfur cluster biogenesis, 
harbors a critical mutation in Friedreich's Ataxia [21] which leads to FTX downregulation in this 
disease [68]. This neurological disorder leads to the degradation of nerve tissue and the spinal 
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cord [21].   Of interest to cancer research is that FTX elicits tumor suppressive activity and is 
downregulated in liver cancer and neuroblastoma [22, 64, 151].  
 
Result 
Iron activates the translational control pathway downstream of Ras/MAPK activation 
The translational control pathway is commonly activated by the Ras/MAPK pathway [1, 
2].  Recently, it has been shown that dual activation of the PI3K and Ras pathway may be 
required to induce the translational control pathway [148].  Based on a Reverse Phase Protein 
Array (RPPA) high-throughput proteomics approach (data not presented), we identified “hits” in 
the translational control pathway.  We validated these hits via western analysis using cell lines 
(T80, T80 + H-Ras, TOV21G, and HEY cells) we previously reported in Chapter 4.  Once again 
these cells were treated with FAC at the 1 hour and 18 hour time points (see Figure 28).  We 
determined that iron exposure leads to activation of the following translational control markers 
including S6, p70S6K, and eIF4E in cell lines that elicited the most marked iron-induced 
reduction in cell survival responses. Specifically, the T80 cell types showed relatively modest 
expression of translational control markers compared to HEY, TOV21G, and T80 + H-Ras cell 
types (see Figure 28).   
Since treatment of iron activated the translational control pathway, we next assessed 
whether inhibition of this pathway could modulate iron-induced sensitivity to reduced cell 
survival response. We inhibited activation of the translational control pathway using 
cycloheximide (a general translational inhibitor) and found no change in cell growth with or 
without iron treatment (data not shown). We then selected a specific inhibitor targeting the MNK 
pathway [152].  The MNK protein is involved in recruiting eIFs to the 5’ UTR region of mRNAs 
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allowing for translation.  Inhibition of MNK reverses translational activation in the presence of 
elevated eIF4E levels [1, 2, 152].  The inhibitor only elicited modest yet significant reversal of 
cell death in HEY cells (see Figure 28).   This indicates that the translational control pathway 
only plays a minor role in the Ras/MAPK-dependent iron induced reduction in cell survival 
response.  In support, we performed siRNA studies targeting p70S6K, S6, and 4E-BP1 but we 
did not observe marked changes in cell survival in the absence or presence of FAC (data not 
shown).    
 
Inhibition of ferroptosis does not reverse iron induced cell survival reduction in HEY and 
TOV21G cell lines              
 Recently, a new form of cell death coined ferroptosis was described [3].   As the name 
suggests, this cell death mechanism is iron-dependent and was found to be distinct from 
apoptosis, autophagy, and necrosis.   Since the exact type of cell death remained elusive in 
Chapter 4, we were interested to determine whether  iron-induced death we observed resembled 
ferroptosis. The cellular characteristics of ferroptosis are not fully delineated. To improve our 
understanding of ferroptosis, we summarize the so far described changes induced under this 
unique mechanism of cell death in tabular format (see Figure 27) from which we concluded that 
ferroptosis appears to be an essentially a form of programmed necrosis or “necroptosis” [3, 71, 
84].   To determine if iron treatment of cell lines with Ras mutation or overexpression led to 
induction of ferroptosis, we assessed the effect of Ferrostatin which was developed by Dixon and 
colleagues [3].  Co-treatment of Ferrostatin with iron led to a reduction in p-ERK, p-AKT, as 
well as autophagic response (see Figure 29).  However, Ferrostatin did not reverse the reduced 
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viability of iron sensitive cells, HEY and TOV21G (up to an equimolar level of Ferrostatin to 
iron).   
 
                    
                          
 
 
 
 
 
 
Figure 28: Iron modulation of the Ras/MAPK pathway activates the 
translational control pathway 
A. T80, T80 + H-Ras, HEY, and TOV21G cells were treated with FAC for 1 
and 18 hour time points.   Phosphorylation of translational control regulators, 
S6 and p70S6K were elevated in HEY, T80 + H-Ras, and TOV21G cell lines.   
B.  Use of a MNK inhibitor hinders activation of the translational control 
pathway.   Treatment with the inhibitor in combination of FAC slightly 
reversed cell death in HEY cells after 96 hours of treatment.   
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Figure 29: Inhibition of ferroptosis does not reverse iron cell death 
A. HEY and TOV21G cells were treated with ferroptosis inhibitor, Ferrostatin-
1 (Ferr-1), at 250 µM concentration.  Cells were treated with and without 
ferrostatin and in combination of FAC (250 µM).   Ferrostatin-1 did not 
reverse iron induced cell death and instead also caused reduction in cell 
growth.    
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FAC modulates iron regulating signals in ovarian cell lines  
 Previously (in Chapter 4), Figure 19 we assessed the expression of ferritin in iron 
treatment.   However, the pattern did not identify any association.  Nevertheless, dysregulated 
expression of molecules involved in iron regulation has previously been demonstrated in cancer 
cells leading to increased iron uptake and intracellular iron retention [25, 69].  Therefore a more 
Figure 30: Iron regulation in ovarian cell types 
A. FAC cell profiles of gynecological cells T80, T80 + H-Ras, HEY, 
TOV112D, and TOV21G do not show a trend with iron regulatory proteins 
(DMT-1, Ferritin, and CD71).   Ras mutation or overexpression does not alter 
response to iron.  Top panel is a 10% gel and the bottom is 8%. 
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comprehensive western analyses of these and other classical iron regulators were performed to 
identify any notable patterns.  We assessed CD71, FTH, DMT-1, as well as ferroportin (see 
Figure 30).  Our data did not reveal any correlations in expression with and without FAC 
treatment across the panel of gynecological cells we assessed.  Since hepcidin (involved in 
internalization and degradation of ferroportin) levels increases in breast cancer, we thus assessed 
its transcript levels relative to HepG2 cells (a hepatocellular carcinoma cell line) [69, 153].  Due 
to the unavailability of hepcidin antibodies, we assessed expressing via real time PCR.  
However, hepcidin mRNA levels was undetectable by real-time PCR methods across all of the 
ovarian cell types investigated while detectable levels in HepG2 cells was detected (data not 
shown). These results suggest that at the intercellular level, hepcidin is unlikely to influence iron 
retention in cell lines with Ras mutation or overexpression.   
 We also investigated the protein expression of IRP1/2 and did not find a distinct trend for 
these molecules across the cell lines tested (T80, T80 + H-Ras, HEY, TOV21G, and TOV112D) 
(data not shown).  Treatment with iron did not alter total IRP1 and IRP2 protein levels.   Since 
we were also interested in determining whether expression of iron regulatory proteins (IRP1 and 
IRP2) could modulate the ovarian cell response to FAC, we performed knockdown of IRP1, 
IRP2, as well as both IRP1/2 (see Figure 31). We observed that the combined IRP1 and IRP2 
knockdown via siRNA, led to >90% reduction of the corresponding protein; however, 
knockdown of both IRP1/2 was needed to decreased expression of ferritin. This finding was 
similar to treatment with U0126 where we observed downregulation of FTH following treatment 
(see Figure 31).  These results suggest that the MAPK pathway is involved in the translation of 
iron regulating proteins, including FTH and CD71.  However, since combined knockdown of  
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Figure 31: IRP1/2 influence on FAC response. 
A. HEY cells were treated with and without FAC and U0126 for 1 hour and 18 
hour time points.  B.  HEY cells were transfected with IRP1, IRP2, or both 
siRNA.  Following 2x transfection, cells were treated with FAC at 1 hour and 
18 hour time points.  
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IRP1/2 did not lead to inhibition of iron induced cell death in HEY cells, other mechanisms must 
account for this reduction in cell survival (data not shown). 
 
Iron hinders mitochondrial functions to modulate cell survival in a Ras/MAPK dependent 
manner 
In Chapter 4, we reported that 24 hour iron treatment of T80 cells led to increased 
numbers of lysosomes.  In contrast, HEY cells treated with iron resulted in a marked reduction in 
lysosome numbers (assessed via Lysotracker Red immunofluorescence staining) (Chapter 4, 
Figure 15).   Interestingly, it was reported that such loss of lysosome integrity may lead to a shift 
of iron localization from the lysosome to the mitochondria [130].  In this respect, we next 
investigated whether iron treatment modulated specific functions of mitochondria differentially 
in the Ras mutated/overexpressing cell lines. Intriguingly, we noted a marked decrease of 
TOM20 and TOM40, outer mitochondrial membrane transporter proteins, in HEY, TOV21G, 
and T80 + H-Ras cell lines treated with iron for 72 hours (see Figure 32).  In contrast, the T80 
and TOV112D cell types showed no reduction in these TOM proteins during the same time 
frame (see Figure 32).  These results suggest that mitochondrial permeabilization may be 
occurring in with a Ras dependent manner in iron treatment. To determine if mitochondrial stress 
was induced by iron, we initially utilized a mitotracker ROS assay.  The immunofluorescence 
assay stains for mitochondria and its fluorescent intensity increases in the presence of ROS (see 
Figure 32).  High fluorescent intensity relative to untreated samples would indicate an increase 
of mitochondrial based ROS.   We found increased mitochondrial staining with T80, T80 + H-
Ras, TOV21G, TOV112D, and HEY cells suggesting increased ROS activity (see Figure 32).  
Interestingly, we determined that iron treatment promoted fragmentation of the mitochondria 
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from a filamentous-like mitochondrial network in all cell types.  This result suggests that 
mitochondrial morphology and its behavior are altered in response to iron exposure.  Next, in 
order to assess whether iron exposure was leading to increased mitochondrial stress, we assessed 
glutathione (GSH) levels in all of the ovarian cell types.  Although there was variability in the 
GSH assay, the results indicated decreased GSH levels with iron treated HEY cells (data not 
shown).  This was further supported with a ROS detection assay showing increased levels of 
ROS in all of the gynecological cell types upon treatment with FAC (see Figure 32).       
Previous reports implicate shuttling of iron into the mitochondria via the calcium 
uniporter channel [62, 63, 130].  In order to assess whether inhibition of this channel could                      
modulate iron-induced cell survival responses, we treated cells with Ru360 (an inhibitor of this 
channel) in combination with/without FAC treatment in HEY cells (see Figure 32). We 
determined that inhibition of this unipoter channel dramatically reversal in cell death (assessed 
using a cell viability assay) (see Figure 32).  This suggests Ras modulated cell types are sensitive 
to iron overload due to import of iron into the mitochondria.  Even more striking, Ru360 in 
combination of FAC reversed the induction of LC3-II (see Figure 32).  This suggests FAC 
induction of autophagy is downstream of iron-induced mitochondrial stress.  Furthermore, this 
preliminary data hints that autophagy activation may specifically be mitophagy (degradation of 
mitochondria via autophagosomes) [24].   
 
 
 
 
 
129 
 
 
                         
               
 
 
 
 
 
Figure 32: Iron modulates mitochondrial functions and leads to cell death 
in Ras modulated cell types 
Continued on following page. 
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Figure 32: Iron modulates mitochondrial functions and leads to cell death 
in Ras modulated cell types 
Continued on following page. 
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Figure 32: Iron modulates mitochondrial functions and leads to cell death 
in Ras modulated cell types 
Continued on following page. 
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Discussion 
In Chapter 4, we determined that iron-induced cell death was correlated to Ras 
mutation/overexpression.  However, we did not elucidate the signaling events downstream of 
Ras/MAPK leading to iron induced cell death.   We hypothesized that activation of AKT and 
ERK may lead to induction of the translational control pathway and thus activation of cell death 
markers.   Our findings suggest that overexpression of Ras leads to the activation of the 
translational control pathway upon treatment with FAC.  However, inhibition of this pathway 
with siRNA or an MNK inhibitor, did not lead to dramatic reversal of cell death.    
 Ras/MAPK dependent cell death response we observed in our cell via iron treatment 
resembled the newly observed cell death mechanism known as ferroptosis.  This mechanism 
resembles necrosis but is specifically mediated by intercellular iron.  We utilized Ferr-1, a 
previously identified inhibitor of ferroptosis, but failed to observe any significant reversal of cell 
Figure 32: Iron modulates mitochondrial functions and leads to cell death 
in Ras modulated cell types 
A.  T80, T80 + H-Ras, HEY, TOV112D, and TOV21G cells were treated with 
FAC for 48 hours and assessed for outer mitochondrial markers TOM20 and 
TOM70.  TOM20 and 70 decreased in iron sensitive cells (T80 + H-Ras, HEY, 
TOV21G) and remained stable in T80 and TOV112D cell lines.   B. We show 
increased ROS in presence of iron at 6 and 24 hours.  This increase was shown 
in all cell lines surveyed.  Measurements were performed using fluorescence 
reading via H2DCFDA (DCF).  Cells treated with hydrogen peroxide (H2O2) 
were utilized as a positive control for ROS.  C. To determine if ROS activity 
was related to loss of the outer mitochondrial membrane markers, mitotracker 
Red ROS was utilized to detect changes in mitochondrial activity at 48 hours 
in T80 and HEY cell lines.   D.  Use of MAPK inhibitor U0126, reversed the 
decrease of TOM20 and TOM70 that occurred as a result of FAC treatment.  
E.  Mitochondrial Calcium Uniporter Channel inhibitor, Ru360, was utilized 
to inhibit iron from entering the mitochondria.  Use of Ru360 reversed FAC 
mediated decreased of TOM20 and TOM70.  F.  Ru360 inhibitor rescued HEY 
cells from the cell viability effects of FAC treatment.   
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death.  While this suggests that the mechanism of cell death observed is not identical to the 
ferroptosis mechanisms reported by Dixon and colleagues [3] , it does not dismiss it all together.   
As stated, the response we observed was markedly similar to ferroptosis.  Further, the 
mechanism of Ferr-1 inhibition was not fully elucidated in previous papers.    It was previously 
determined that ferrostatin did not interact with the Ras/MAPK pathway nor does it chelate iron 
particles [3].  The only specific function observed was its ability to reduce ROS implicating its 
antioxidative capabilities [3].   It is possible that the inhibitor is selective for specific cell types or 
takes advantage of an iron regulatory process not involved in ovarian cells.    
 In Chapter 4, we successfully showed that Ras mutation/overexpression to be critical to 
iron-induced cell death.  The question lingering was what signaling pathways were activated 
downstream of.  We hypothesized Ras may influence the iron regulatory pathway by modulating 
absorption, retention, storage, or a combination of all three systems.   We found that iron 
regulating proteins (CD71, ferritin, DMT-1, ferroportin, and hepcidin) were not modulated due 
to Ras mutation expression (see Figure 30).   Further, the translational regulation of these 
proteins (IRP1/2) was also not critical in inducing cell death.  Interestingly, the loss of IRP1 and 
IRP2 led to a reduction in cell survival in untreated HEY cells implicating IRPs’ role as a tumor 
promoter.   
 Similar to cellular iron regulation, the mitochondria also has means of importing, storing, 
and exporting iron.   Interestingly, iron plays a critical role in regulating aconitase activity of 
IRP1 that is essential in the conversion of citrate to glutamate (in a three step process) [21].   One 
core regulator of iron mitochondrial regulation is frataxin.  This protein is considered a tumor 
suppressor and has been identified to be modified in cancer cell types [19].   We were unable to 
detect frataxin with the antibodies currently available for western detection. As an alternative, 
134 
 
future investigations could quantify levels of mRNA via RT-PCR. Interestingly, we reported a 
marked decrease of OMM proteins, TOM20 and TOM70, in Ras sensitive cell lines (HEY, 
TOV21G, and T80 + H-Ras) (see Figure 32).  This suggests that the iron regulation in the 
mitochondria is dysregulated in Ras mutated/overexpressing cell types possibly leading 
permeabilization.  Further, mitotracker staining revealed that iron treatment modulates 
mitochondrial structure suggesting that this organelle plays a role in general iron regulation in 
ovarian cell lines.  Perhaps the most striking data that we identified in this chapter was the 
response to inhibition of the calcium uniporter channel.   Indeed, inhibition of this channel 
reversed the cell death effects of iron in HEY cells suggesting that iron sensitivity is directly 
linked to mitochondrial dysfunction in Ras mutated/overexpressing cell types (see Figure 32).  
Further, reversal of FAC induced LC3-II via Ru360 suggests the induction of autophagy could 
potentially be mitophagy (see Figure 32 and 33).   
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Figure 33: Model of signaling pathways that are activated by iron in 
gynecological cell types.  
Continued on following page. 
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Figure 33: Model of signaling pathways that are activated by iron in 
gynecological cell types.  
A.  Iron enters the cell through the transferrin receptor leading to activation of  
p-AKT and p-ERK.  Both pathways help to induce translational control 
activation leading to partial cell death.  The other roles for activated AKT via 
iron treatment are yet unknown.  Activation of the MAPK pathway induces 
autophagy and lysosomes.  Further, iron treatment leads to mitochondrial 
stress and elevated ROS levels.   Increased or mutated Ras may lead to 
decreased lysosome numbers (as seen in HEY cells).  Loss of lysosomes may 
augment mitochondrial stress leading to mitochondrial permeabilization and 
cell death.   B.  Upon entering the cell, iron can be taken up by the lysosome to 
allow for protection and survival.  However, in the presence of 
mutated/overexpressed Ras lysosomes are permeabilized. The lack of 
lysosomes as a result of activated Ras may result in mitochondrial 
permeabilization and cell death [21, 28, 29].  *Model created by Kyle 
Bauckman. 
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Chapter 7 
 
Final Discussion and Future Directions 
 
Overview 
 We present herein, an in-depth study of the role of iron response in gynecological cell 
lines.  In Chapter 3, we developed a novel epithelial endometriotic lifespan extended cell line 
that can be utilized for intracellular iron research along with future mouse xenograft studies.   
Next, we investigated the effect of iron response on a panel of gynecological cell lines (Chapter 
4).  Intriguingly, we identified cell lines that contain Ras mutations or increased expression of 
Ras which were sensitive to iron.   This sensitivity resulted in reduced cell viability and cell 
death in Ras specific cell lines.   Iron activated multiple signaling pathways including AKT, 
MAPK, autophagy, and the translational control pathway (Chapters 4 and 6).  Interestingly, 
inhibition of the MAPK/ERK pathway reversed iron-mediated reduction in cell viability with 
Ras sensitive cell lines.    
 Next, we investigated the effect of iron on ATP levels, adherence, migration, cell cycle, 
and ability to modulate anoikis.   Chapters 4 and 5 explore these responses in gynecological cell 
types; we found that iron altered cell migration and cell cycle with little effect on cellular 
adherence.  Further, cells grown under anchorage-independent conditions had reduced levels of 
cleaved PARP in the presence of iron.   This suggests that iron antagonizes the apoptotic 
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response in detached cells thus promoting continued survival.  Studies are currently ongoing to 
further elucidate the iron-induced mitochondrial response of gynecological cell types presented 
in this thesis.  In Chapter 6, we provide evidence of mitochondrial permeabilization upon iron 
treatment leading to cell death in a Ras sensitive cell line (HEY, serous ovarian cell line).    
 
Connection to Original Hypothesis 
We hypothesized that continuous iron treatment would induce “normal” cells to grow, 
leading potentially to carcinoma-like characteristics.  The work presented in this thesis 
uncovered a previously unknown iron response in gynecological cell lines.   However, our 
findings superficially appear to contrast with our initial hypothesis and previously published 
iron/cancer publications [20, 25, 69].  Iron is a critical element essential for cell growth and 
beneficial to multiple cancer types including breast cancer and leukemia [20, 25].  Further, high 
iron exposure is linked to transformation of normal cells and increased toxicity [13, 20, 34, 70].   
Iron is one of the most critical elements for survival; however,  no mechanisms have  
been identified that would be responsible for eliminating iron from the body [25].  Many of the 
iron regulatory mechanisms in the cell are involved in import, export, utilization, and metabolic 
purposes [19, 25, 27].  Iron has been reported to increase ROS production which at constant 
levels could prove detrimental for organs (i.e. liver cirrhosis) and cell survival [20, 26, 70, 71, 
130].  High iron levels have been shown to promote cell growth in a cancer cell system [25].  
The mechanisms may be due to increased levels of transferrin receptor, HO-1, and proteins 
involved in iron regulation [25, 35, 65, 69, 154].  Advanced stages of cancer have also been 
correlated with increased risk of anemia suggesting the cancer cells are involved with increased 
uptake of iron from the microenvironment [27].    
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We hypothesized that “normal” gynecological cells maintained in an iron rich 
environment would elicit characteristics of an ovarian cancer tumor.  Our studies presented in 
Chapter 4 compared “normal” cells vs. cells from different subtypes of ovarian cancer (serous 
carcinoma, clear cell, endometrioid).   We expected ovarian cancer cell lines to exhibit increased 
proliferative capacity with iron while the “normal” cells would initially show increased cell 
stress.  However, our serendipitous findings, reported in Chapter 4, identified an iron-induced 
Ras/MAPK dependent cell death mechanism.   The focus of the thesis shifted from the role of 
iron in normal cells to elucidating the cell death response and mechanism in Ras mutated cell 
lines in response to iron.   While the findings presented are novel, we now attempt to connect 
these findings with the original hypothesis.  In the words of T.S Eliot, “the end of our exploring 
will be to arrive where we started and know the place for the first time [155].”   
Our results presented in Chapter 4 conflict with data from previous reports and our 
proposed hypothesis on iron’s transformative/proliferative properties [13, 20, 25, 34].  Our data 
suggests that iron may be beneficial to patients with ovarian cancer tumors (those containing Ras 
mutations).   However, our observations may implicate a more intriguing event.   In Chapter 3 
we observed that long term iron treatment in HEY cells (K-Ras mutated serous carcinoma cell 
line) led to significant decrease in cell growth and increase in cell death.  However, a small 
population of HEY cells would remain viable after 96 hours of treatment.   These cells survived 
and apparently divided with continual exposure to iron beyond 96 hour leading to a fully 
confluent cell culture.  This suggests that a small percentage of the HEY cells were resistant to 
iron-induced cell death.   While it is not unusual for cancer cells to develop resistance to drug 
and chemical treatments, it is perhaps more alarming to observe the phenomenon with iron 
treatment.  Indeed, this may be harmful rather than beneficial.    Iron induces a very strong cell 
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death response toward ovarian cancer cells with Ras mutations.  The rapid cell death response we 
observe in Ras mutated cancer cells may be a means of natural selection.  Another possibility is 
that iron may be selecting for HEY cell populations lacking Ras mutations.   The small 
population would then be unaffected by continued iron exposure thus promoting its growth.   
One could determine if this is occurring by sequencing K-Ras in the iron resistant population and 
identify if the mutation is still present.    
We have also observed changes in the normal ovarian surface epithelial cell type, T80, 
and the epithelial endometriotic lifespan extended cell line (IE).  T80 and IE cells displayed 
distinct morphological (spindle-like characteristics) changes upon treatment with iron.  Though 
we observed changes in cell size, we did not detect changes in overall growth via crystal violet 
staining.   This discrepancy may be due to the experimental technique utilized to assess cell 
viability.   We performed crystal violet staining which stains protein but is not a direct 
measurement for proliferation.   Thus, BrdU staining should be used to assess if the resistant 
cells are proliferating (in S phase).  Our cell cycle analysis demonstrated G1 arrest utilizing 
whole cell populations.  We may identify increases in S phase with the iron-resistant population.   
 
In Vivo Response to Iron  
 The data presented in this thesis is exclusively in vitro based experiments.  This allows a 
study of the mechanisms inducing iron cell death response; however, it does not provide data on 
the role of microenvironment in tumor development.  As stated in Chapter 1, endometriotic cysts 
arise via retrograde movement of endometrial glands to the surface of the ovary [30, 33, 52].    
These cysts contain elevated levels of heme which is proposed to transform the endometriotic 
tissue leading to the development of ovarian cancer [13, 40].    The surface of the ovary may be 
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exposed to high iron promoting cell stress leading to transformation [13, 40].   Unfortunately, the 
lack of precursor and early stage ovarian cancer specimens has made it challenging to support 
this idea.  Thus, there is a lingering question of what precursor tissue/cells are leading to ovarian 
cancer development.   Strong evidence suggests that ovarian cancer originates from the fallopian 
tube, the endometrial lining, as well as the surface of the ovary [13, 16, 46, 47]. 
 Iron exposure may drive development of tumors from endometriotic cysts [13].  Indeed, 
in Chapter 6, we have shown that iron increased ROS; this could lead to cellular transformation 
by modulating cell signaling pathways [13, 20].  Excess iron (due to endometriotic cysts bursting 
and releasing iron into the microenvironment) could elicit cell stress to the ovary.  This stress 
may lead to induction of an inflammatory response in the microenvironment.  We propose that 
iron acts as a tumor initiator and the stress that is generated could potentially lead to 
transformation of the ovarian epithelial cells [89].    
 Interestingly, iron has similar characteristics to asbestos-mediated tumor development.   
Neither compound acts as a carcinogen but their ability to induce cell stress can lead to 
tumorigenesis nonetheless [20, 156].   It would be interesting to investigate ovarian cancer risk 
factors in women with high iron diets; no such study exists thus far.    
 As mentioned above (see Connection to the Original Hypothesis section), long term 
iron treatment eventually led to resistance in a subpopulation of cells.  From an in vivo 
perspective, iron may destroy tissue leaving a denuded region that could be filled in by 
transformative cells.  This behavior may allow for progression of a more aggressive tumor type 
in vivo.  Iron may not result in massive cell death in vivo due to influence via the endocrine 
system.  For example, hepcidin a small peptide hormone produced from the liver, promotes 
intercellular iron retention by degrading ferroportin which is involved in iron export [27, 69].  
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Further, hepcidin has been linked to increased iron levels in breast cancer in in vivo studies [27, 
69].  The gynecological cell types we investigated had undetectable levels of hepcidin mRNA 
relative to HepG2 cells (liver carcinoma cells) which showed decreased levels of hepcidin 
mRNA with iron treatment (data not shown).  This suggests that hepcidin does not contribute a 
large degree in iron regulation in the gynecological cell types we investigated.   However, our 
hypothesis was that hepcidin would increase intercellular iron leading to iron toxicity in Ras 
mutated cancer cells.  In Figure 34 and 35, we present a model describing development of 
ovarian cancer in the presence of iron and the in vivo response of Ras mutated ovarian cancer to 
iron. 
 
Limitations 
 While our data strongly support our conclusions, we have not successfully answered the 
initial hypotheses.   Each chapter was met with limitations and unanswered questions that we 
discuss below.   
Chapter 3 focused on the development of a novel extended lifespan epithelial 
endometriotic cell line.   Although we were successful in developing and characterizing such a 
cell line, we were unable to perform the many assays utilized in established cell lines due to its 
limited lifespan.  The primary cells were challenging to immortalize as they were very sensitive 
to the retroviral infection process.  This hindered the development of a SV40 Large T antigen / 
hTERT immortalized cell type.   As a result, the passage number for the cell line was limited to 
around 20.   As described in Chapter 2 (see Table 2), very few epithelial endometriotic cell lines 
are currently available.   We hope that our continued efforts will eventually contribute a new cell  
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Figure 34: Role of Iron in Ovarian Cancer Initiation in vivo. 
1. Endometrial glands (comprised of epithelial and stromal tissue) travel 
upward through the fallopian tube and attaches to the surface of the ovary 
leading to the development of an endometriotic cyst rich in iron.  In Chapter 5, 
we demonstrate iron reduces anoikis (based on cleaved PARP decrease) (see 
Chapter 5, Figure 24).  2a. Endometriotic cysts containing iron rich heme form 
on the ovary. Iron rich heme present in the endometriotic cyst is released 
leading to increased ROS, cell signaling, and autophagy activation (see 
Chapters 4 and 6).  3a. Continual iron exposure transforms endometriotic 
epithelial cells to early stage tumors that eventually lead to invasion and 
metastasis.   2b/3b. Another pathway of tumorigenesis may stem from the 
content of endometriotic cysts influence on the surface of the ovary.   Cyst 
burden may elicit an environment with inflammation (NK cells and 
macrophages) and hormone dysregulation (particularly estrogen) leading to 
transformation of ovarian tissue [13, 16, 18, 20, 30-33].   *Model created by 
Kyle Bauckman. 
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Figure 34: Model of Iron Influence in Ovarian Cancer Progression in vivo    
1. Iron present in the microenvironment could influence ovarian cancer.  This 
may lead to pathways 2 through 4.  Pathway 2: if the tumor microenvironment 
has high levels of hepcidin, intercellular levels of iron would increase leading 
to high cell death in Ras mutated cell types.   Pathway 3: Absence of hepcidin 
would also induce cell death response as seen in vitro (see Chapter 4).  
Pathway 4:  Regulation of iron via equilibrium of hepcidin in the 
microenvironment may reduce the cell death effect observed.  Pathway 5:  
Continual exposure to increased intercellular iron will lead to selection of cells 
tolerant to iron therefore to a potentially more aggressive/invasive tumor will 
develop (6.) [13, 25, 27, 28]. *Model created by Kyle Bauckman. 
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line to the field.  We are presently characterizing and validating more endometriotic cell lines for 
future use.    We have gained valuable knowledge in care and development of IE cells. 
In Chapter 5, we observed a significant reduction of cell growth with Ras mutated or 
overexpressed cell types.   We investigated multiple mechanisms of cell death; specifically in the 
HEY cell line we discovered marked iron induced necrotic activity (see Chapter 4, Figure 11).  
However, we were not successful in identifying the cell death behavior of the other Ras sensitive 
cell lines (TOV21G, T80 + H-Ras).   We investigated multiple cell death mechanisms including 
apoptosis, necrosis, autophagy, and ferroptosis; however, these mechanisms did not appear to 
contribute to decreased cell viability observed in the TOV21G and T80 + H-Ras cell lines.   
Some of these shortcomings may be due to limitations in the experimental procedures performed.  
Although we did not observe cleaved PARP in iron-treated TOV21G cells using methods 
presented in Chapter 4, we do see slight increase of cleaved PARP in TOV21G cells treated with 
iron in data presented in Chapter 5.  The protocol for analyzing cell death in Chapter 5 required 
collection of floating cells (not performed in any other western analysis presented in Chapter 4).  
Thus it is possible only the floating cells express cell death markers.  Another possibility is 
apoptosis may be occurring via a caspase-independent mechanism [72].    Another dilemma 
arose with the ferroptosis inhibitor, ferrostatin.   Our studies with the ferroptosis inhibitor 
demonstrated high toxicity indicating it was too potent for the selected gynecological cell lines 
(see Chapter 6, Figure 29).  This does not indicate ferroptosis is not being induced, but simply 
that the inhibitor is too potent for the selected cell types.  Future investigations should focus on 
finding alternate inhibitors for the ferroptosis process or alternatively screen for inhibitors that 
reverse the iron-induced cell death our studies delineate.    
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 Elucidation of the signaling pathway induced by iron treatment proved the most 
challenging aspect of the project.  The current literature related to iron and ovarian cancer is 
limiting and iron’s role in ovarian cancer cell death is non-existent (excluding our recent 
publication).  Multiple signaling pathways are activated via iron treatment; however, these events 
did not contribute to iron-induced cell death.  This is logical considering that iron is a naturally 
occurring element in the cell and required for basic metabolic functions.   We have identified that 
the cell death mechanism is Ras/MAPK dependent (see Chapter 4, Figure 16) and induces both 
lysosomal (see Chapter 4, Figure 16) and mitochondrial permeabilization (see Chapter 6, Figure 
32).  We also observed that the loss of mitochondria is directly linked to cell death induction in 
HEY cells (see Chapter 6, Figure 32).   
 Though we were successful in uncovering these important signaling pathways involved 
in iron- induced cell death, the links between these pathways has yet to be investigated.  Some 
questions that arise include how does a Ras mutation influence lysosome and mitochondrial 
permeabilization?  We attempted to determine if Ras mutations induced higher intake of iron, but 
technical issues prevented us from pursuing this.   Future endeavors should focus on finding a 
method of accurately assessing intercellular iron intake.    
Effort should also be placed in determining the kinetics of the iron-induced events.   We 
have identified activation of pERK to occur early (1 hour or less) (see Chapter 4, Figure 16) 
which led to increased production of lysosomes at 24 hours (see Chapter 4, Figure 15).   At the 
same time, mitochondrial stress was also observed at 24 hours followed by loss of outer 
mitochondrial markers at 48 hours (TOM20/70) (see Chapter 6, Figure 32).   The remaining 
question is what is the specific cellular mechanism that can lead to the observed cell death?   We 
propose that loss of lysosomes leads to increased mitochondrial stress and permeabilization or 
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vice versa.  Western blots and flow cytometry assess the entire cell population and thus the 
overall trends; these methods may miss events occurring in smaller populations.  For example, 
we observed lack of lysosome formation in necrotic HEY cell population treated with iron.   
However, in the resistant population, we noted abundant lysosomes present.   It would be 
interesting to observe mitochondrial response in this population.  Therefore, it may be 
advantageous to perform single cell, live imaging of HEY cells treated with iron.   These cells 
could be tagged with lysotracker and a mitotracker and imaged over 48 hours to determine the 
specific chain of events leading to iron-induced cell death.   
  
Summary of Future Directions and Proposed Specific Aims 
 The data presented in this thesis describes a novel discovery that we foresee to evolve 
into multiple future investigations (some of which are ongoing).  The role of iron in ovarian 
tumor growth in vivo would be the core focus of the investigation.  The cellular response to iron 
may drastically change with the addition of the microenvironment.  The effect we observe in 
vitro may select for cells lacking Ras mutations and/or may promote a more aggressive 
phenotype.  As stated, the limitation with IE cells (inability to expand cells beyond 20 passages) 
hinders experimental progress.   Continued endeavors also include development of a more 
immortalized endometriotic cell line which would be useful for long term iron studies. We are 
currently in the process of immortalizing two primary endometriotic cell lines derived from the 
peritoneal cavity and ovary, respectively.   
 Finally, it is important to address the role of DFO on ovarian cancer growth.   Treatment 
with DFO in gynecological cell lines induced high levels of cell death in the form of apoptosis 
(see Chapter 4, Figure 19).   This response occurred with doses as low as 1 µM.  This is 
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particularly impressive with consideration that typical doses of DFO range from 200-300 µM in 
vivo [11].  This suggests DFO may be an ideal drug for ovarian cancer treatment.   The only 
negative detail is DFO is toxic to all gynecological cell types.   This suggests in vivo treatment 
may lead to toxicity to all gynecological tissue.   
   
Development and Characterization of Novel Endometriotic Cell Lines 
Aim 1: Characterize additional primary endometriotic cell lines 
1.1 : Determine if cells are stromal or epithelial  
1.2 : Assesses markers of growth, survival, cell cycle, and EMT relative to 
existing ovarian cell types 
Aim 2: Immortalize primary endometriotic cell line 
 2.1: Immortalize cells with hTERT 
 2.2: Characterize confirming immortalization and retention of similar proteomic profile 
expressed in primary cells. 
Aim 3: Determine the role of autophagy in endometriotic cell survival 
 3.1: Inhibit autophagy and assess immortalized cell survival  
 
Iron modulates cell survival in a Ras- and MAPK-dependent manner in ovarian carcinoma (in 
vivo) 
Aim 1: Determine the influence of iron in mouse ovarian tumor models (Dinulescu’s model [93]) 
           1.1: Determine if cell death markers are present following iron treatment provided 
intratumorally.  
           1.2: Determine time of reoccurrence of tumor burden  
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Aim 2: Determine the phenotype and genotype of long term iron treated HEY cells 
           2.1: Is K-Ras mutation present in the resistant population (In vitro)? 
           2.2: In vivo mouse xenograft model using long term treated HEY cells to determine 
invasiveness, proliferative capacity, and metastatic potential.   
Aim 3: Determine whether there is an association between high iron diet and ovarian cancer.  
3.1: Determine if select populations of ovarian cancer patients can be classified according
 to their blood iron and/or tumor iron levels.   
 3.2: Assess whether increased iron intake increase ovarian cancer risk? 
 
The cell death effect of DFO on ovarian cancer in vivo  
Aim 1: Ovarian cancer mouse model studies 
1.1 : Determine if DFO treatment reduces growth of ovarian tumors 
1.2 : Determine lowest dose required for clearance of tumor burden 
Aim 2: Phase 1 clinical trials of DFO on ovarian cancer patients 
 2.1: Treat with DFO with and without an iron limited diet to determine efficacy of drug 
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